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ABSTRACT 
Sickle cell anaemia (SCA) is an autosomal recessive inherited haemoglobinopathy, 
characterized by chronic haemolysis and inflammation, frequent infections and 
recurrent vaso-occlusive crisis (VOC). The hallmark of VOC is severe acute pain due 
to ischaemic tissue injury. The resultant end organ damage contributes to the 
significant morbidity and mortality observed in this disease. Genetic and 
environmental interactions result in a variable phenotype.  
This study investigates the most common complications in SCA, including VOC and 
infections. Specifically, phagocytic activity of neutrophils and monocytes in the 
pathogenesis of SCA, and the most frequent bacterial infection. Furthermore, the 
study investigates changes in leukocytes subsets and the relationship between cell 
adhesion molecules expression and disease manifestations in patients during steady 
state and acute VOC.  
The results indicate that staphylococcus aureus is the most common organism isolated 
in SCA related infections, followed by Escherichia coli and Pseudomonas 
aeruginosa.  
There was no significant difference in phagocytic activity between both patient 
groups and control subjects. Lymphocyte subsets showed high percentages of total T 
lymphocytes, T helper and suppressor lymphocytes, B lymphocytes as well as NK 
cells in patients with SCA during steady state, while B lymphocytes and NK cells 
were significantly higher during acute VOC crisis, in comparison to control group. 
One of most important and novel findings of the present study in Saudi Arabia was 
the presence of high levels immunophenotypic expression of L-selectin on 
neutrophils, monocytes and lymphocytes during acute VOC in comparison to normal 
control subjects. Accordingly, as markers for leukocytes activation, L- selectin can be 
XVII 
 
used as a predictor for VOC, which of value in the early diagnosis and intervention of 
these painful episodes.  
In addition another anoval finding, is the  high levels of both soluble E- selectin (sE- 
selectin), soluble P- selectin (sP- selectin) markers were demonstrated in the serum of 
patients with SCA during both steady state and acute VOC.  Levels of selectins were 
significantly higher in acute VOC.  
These findings suggest that patients with SCA have intact phagocytic activity and 
increased expression of adhesion molecules; L- selectin, E-selectin and P-selectin, 
which play an important role in the pathogensis of VOC.  
While sickle cell disease is a well-recognized state of chronic inflammation, the role 
of specific adhesion molecules should be further elucidated. Studies are needed to 
investigate the potential role of selectin antagonists, for prevention and reversal of 
acute vascular occlusions in SCA patients.  
  
  
 
 
CHAPTER 1  
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CHAPTER 1: GENERAL INTRODUCTION 
Sickle cell anaemia (SCA) is a common inherited haemolytic disorder characterised 
by chronic haemolysis, frequent infections and recurrent vascular occlusion of small 
and large blood vessels. Recurrent vaso-occlusive crises (VOC) results in chronic 
organ damage and ultimately organ failure, and can lead to morbidity and mortality. 
Moreover, the chronic inflammation and infection increase cell adhesion molecule 
expression, which precipitate vaso-occlusive crisis (Ataga & Key, 2007; Makis et al., 
2000; Matsui et al., 2002).  
Sickle cell anaemia is caused by a mutation of the gene encoding the β-chain of 
haemoglobin. This mutation leads to the production of sickle haemoglobin, which has 
an abnormal tendency to polymerise. Haemoglobin S polymerisation and denaturation 
results in oxidant damage to the red blood cell membrane, with subsequently 
disturbed homeostasis which in turn, can result in dehydrated dense cells and 
irreversibly sickled cells. Red cell abnormalities lead to either haemolysis or vaso-
occlusion. Vaso-occlusion results from interaction between red cells, leukocytes and 
endothelial cell inflammation, endothelial injury, leukocytes adhesion and activation 
of coagulation pathways contribute to the pathophysiology of vaso-occlusive crisis. 
The clinical hallmark of SCA is the excruciating pain, associated with sickle cell 
crisis. Such crisis occurs with variable frequency and duration, and they commonly 
require hospitalisation. Frequent attacks of painful crisis result in serious morbidity 
and hamper quality of life (Mousa et al., 2010).  
Sickle cell anaemia is frequently seen in sub-Saharan and Western regions of Africa, 
where 15-30% of the population carry the abnormal sickle cell gene (World Health 
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Organization, 2006; Weatherall & Clegg, 2001). Each year, between 300,000 and 
400,000 infants are born with major haemoglobin disorders including more than 
200,000 cases of sickle cell anaemia in Africa, with 150,000 in Nigeria alone 
(Banerjee et al., 2001). 
The wide distribution of the sickle cell gene is the result of survival advantage, which 
provides protection of the heterozygote against malaria infection. The prevalence of 
carriers in the Middle East and some parts of India ranges from 5 to 40% or more of 
the population (Hoffbrand et al., 2006; Kumar & Clark, 1994) (Figure  1.1).  
Sickle cell anaemia is also found in Arab and Mediterranean countries, the India 
subcontinent, the Caribbean and the Southern United States (Hoffbrand et al., 2005; 
Hoffbrand et al., 2006; Williams et al., 2001). The epidemiology of SCA in Arab 
region and the high prevalence of the mutation are well documented. A study 
conducted in the populations of Bahrain and Oman, reported a prevalence of sickle 
cell trait of 11.2% and 6% respectively (Al-Hamdan et al., 2007; Mohammed et al., 
1992; Mousa et al., 2010). 
In Saudi Arabia, the distribution of SCA is primarily in the Eastern, Western, and 
South Western provinces. As part of the Saudi National Premarital Screening 
Program, the prevalence of beta-thalassaemia and sickle cell disorders have been 
determined in the adult Saudi population. Notably, out of 488,315 individuals 
screened, 4.2% had sickle cell trait whilst 0.26% had sickle cell disease (Al-Hamdan 
et al., 2007).  
  
3 
 
 
 
 
Figure  1.1 Geographical distribution and schematic representation of the sickle cell gene. The 
map identifies the three distinct areas in Africa and one in the Arab-India region where the sickle  
cell gene is present (dotted lines). The number of individuals with sickle-cell disease (red lines) in 
Senegal, Benin and Bantu are higher near the coast, and falls concentrically inland. Adapted 
from (Stuart & Nagel, 2004).  
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Extensive studies, conducted in different provinces of Saudi Arabia, have shown that 
a wide distribution pattern of haemoglobin S gene is present in different provinces. 
The overall prevalence of haemoglobin S carriers varies from 7% in the Western, 12% 
in the Southern, and approximately 25% in some parts of Eastern region (EI-Hazmi & 
Warsy, 1999; El-Hazmi & Warsy, 1994) 
Perrine et al. (1978) established that serious complications including jaundice, spleen 
damage and haematuria occurred in Saudi patients less frequently than that reported in 
North American Blacks (6% Saudi versus 25% American Blacks) (Perrine et al., 
1978). 
Between 1995 and 1999, about 256 patients were diagnosed with SCA at King 
Abdulaziz University Hospital (KAUH), either through our haematology clinic or the 
emergency department. There is a large body of evidence that the pathogenisis of 
SCA, the different clinical presentations, and complications are influenced by several 
variables, including the epistatic factors, adhesion mechanisms, coagulation 
activation, and leukocyte functions. Consequently, the effects of these variables were 
studied independently, and new approaches in the management of VOC were 
explored. 
1.1 History 
The first age of the haemoglobinopathies commenced in 1904, when Horrick first 
discovered sickle cell anaemia and continued with the identification in 1949, Pauling 
and Itano, of the presence of an electrophoretically abnormal component in the 
haemoglobin of patients with sickle cell anaemia (Stuart & Nagel, 2004). The 
identification of the cause of this change in mobility had to await the development of 
peptide mapping by Ingram in 1956, in 1963; Ingram confirmed that all patients with 
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sickle cell anaemia had the same substitution of valine for the glutamate in position 6 
of the beta globin chain. This defect was subsequently identified as a single nucleotide 
mutation in the gene, which results in easy polymerisation of the abnormal 
haemoglobin (Matsui et al., 2002). 
1.2 Epidemiology 
Worldwide, there is limited information on the exact number of individuals affected 
with homozygous sickle cell anaemia (SCA). The World Health Organization’s global 
prevalence map of SCA suggests that approximately 20–25 million individuals 
worldwide are homozygous for HbS; with 12–15 million in sub-Saharan Africa, 5–10 
million in India and approximately 3 million distributed across different parts of the 
world (Serjeant, 2006). In the United States of America (USA) approximately 70,000 
patients with SCA have been registered. The life expectancy has improved amongst 
patients living in the USA and Western Europe, which means that organ 
complications associated with older age are now being observed with increasing 
frequency in adults. Furthermore, pulmonary hypertension, avascular necrosis of the 
femoral head, nephropathy, cholelithiasis, retinopathy, cardiomyopathy, and delayed 
growth and sexual maturation are frequent long term complications associated with 
increased morbidity and mortality (Aliyu et al., 2008). 
In many places, despite more than a decade of work, epidemiological data are still 
fragmentary. Precise population data and accurate gene frequency estimation are 
needed in order to define the magnitude of the problem in a given country. 
Furthermore, a phenotype screening for HbS usually provides epidemiological data 
(Labie & Elion, 2002; Williams et al., 2001). With this in mind, sickle cell screening 
at birth is the most effective method and it is a common practice in the USA. This 
type of screening has also been implemented in European countries, owing to 
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increasing immigration from Africa or Western India. Moreover, cost efficiency of 
screening has been demonstrated using isoelectric focusing performed from dried 
blood spots on filter paper disks (Ryan et al., 2010). In African countries, screening at 
birth may be problematic owing to the fact that the majority of deliveries take place at 
home and not in hospital (Labie & Elion, 2002).  
1.3 Pathophysiology 
Sickle cell anaemia is as an autosomal recessive trait, caused by a single-base 
mutation of adenine to thymine in the gene encoding the beta globin (β-globin) chain 
on chromosome 11. This modification leads to substitution of one glutamic acid 
residue by valine in the 6 position of the same chain (Hoffbrand et al., 2006; Williams 
et al., 2001) 
In the homozygous state, both β- globin genes are abnormal (HbSS); however, as the 
synthesis of foetal haemoglobin (HbF) is normal, the anaemia usually does not 
manifest itself until the HbF production decreases to adult levels, at approximately 6 
months of age (Hoffbrand et al., 2005; Hoffbrand et al., 2006; Williams et al., 2001). 
Vaso-occlusion results from a combination of abnormalities in the haemoglobin 
structure and function, a loss of red blood cell membrane integrity, the promotion of 
inflammatory mediators, activation of endothelial cell adhesion, disrupted vascular 
smooth muscle function, and enhanced coagulation (Aliyu et al., 2008; Chiang & 
Frenette, 2005). 
The clinical situations in which the red cell undergoes low oxygen tension, 
deoxygenation, will induce potassium efflux and increased red cell density, as well as 
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the tendency of haemoglobin S to polymerise. These cells then line up to form 
crystals known as tactoids (Horiuchi et al., 1990). As a result, the intracellular 
contents of abnormal haemoglobin become more viscous and the flexibility of the red 
blood cells is decreased, so that they become rigid and form the sickle shape during 
their passage through the microcirculation. The process is initially reversible, but with 
repeated sickling, the cells eventually lose their membrane flexibility and remain in 
the irreversible sickle form (Williams et al., 2001) (Figure  1.2). 
Haemolysis contributes to dysregulation of nitric oxide. Nitric oxide (NO), produced 
by endothelial NO synthase, reacts with free haemoglobin to produce met-
haemoglobin and nitrate which leads to NO depletion. Nitric oxide has a major role in 
maintaining the integrity of vascular homeostasis, whereby it regulates and mediates 
smooth muscle relaxation and vasomotor tone; it down-regulates endothelial adhesion 
molecule expression and inhibits platelet activation and aggregation (Mack & Kato, 
2006; Reiter et al., 2002; Rother et al., 2005) (Figure  1.3).  
The abnormal adhesiveness of sickle red blood cells to endothelial cells slows the 
transit of blood cells through small vessels and precipitates in the occurrence of VOC 
(Hoffbrand et al., 2005; Odièvre et al., 2008). Notably, the adherence of sickle red 
cells to endothelial cells is a complex process requiring interactions between multiple 
adhesion molecules. Cell adhesion molecules (CAM) on the red blood cell include 
integrin α4b1(VLA-4), α5b3 integrin and CD36 (thrombospondin receptor) and are 
expressed on young reticulocytes (Telen, 2001, 2005), whilst endothelial adhesion 
molecules include endothelin-1, vascular cellular adhesion molecule-1 (VCAM-1), 
intracellular cell adhesion molecule-1 (ICAM-1), basal cell adhesion molecule 
(BCAM), platelets selectin (P-selectin), endothelial selectin (E-selectin) and 
fibronectin (Okpala, 2004b, 2006).   
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Figure  1.2 The schematic representation of the molecular basis of the pathophysiology of vaso-
occlusion interactions. (A) Single nucleotide substitution (GTG for GAG). (B) HbS 
polymerisation. (C) Cell shape changes of HbS-polymer-containing erythrocyte. (D) Cross-
section of microvascular bifurcation. EC=endothelium. R=reticulocyte. ISC=irreversibly sickled 
cell. N=leukocyte. N:O =NO bioavailability. RBC=red blood cell. Luminal obstruction has been 
initiated by the attachment of proadhesive reticulocyte to endothelium with secondary trapping 
of irreversible sickled cells. Leukocytes participate in formation of heterocellular aggregates, and 
NO bioavailability, crucial to vasodilation, is impaired. Adapted from (Stuart & Nagel, 2004).   
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Figure  1.3 Intravascular haemolysis reduces (NO) bioactivity. Nitric oxide is produced by 
isoforms of nitric oxide synthase, using the substrate L-arginine. Intravascular haemolysis 
simultaneously releases haemoglobin, arginase, and lactate dehydrogenase (LDH) from red cells 
into the blood plasma. Cell-free plasma haemoglobin stochiometrically inactivates NO, 
generating methaemoglobin and inert nitrate (A). Plasma L-arginase subsequently consumes 
plasma L-arginine to ornithine, thereby depleting its availability for NO production (B). LDH 
also released from the red cell into blood serum serves as a surrogate marker for the magnitude 
of haemoglobin and arginase release. NO is also consumed by reactions with reactive oxygen 
species (e.g., O2-) produced by the high levels of xanthine oxidase activity and NADPH oxidase 
activity seen in sickle cell disease, producing oxygen radicals like peroxynitrite (ONOO-)(C). 
These radicals also decrease NO bioactivity. Adapted from (Kato et al., 2007).   
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Subendothelial matrix components and plasma proteins such as thrombin, interleukin-
1 (IL-1) and tumours necrosis factors form bridges between the red cells, endothelial 
cells and leukocytes, and  also play a major role in the adhesion process (Steinberg & 
Rodgers, 2001). 
High granulocyte count is a risk factor for death in sickle cell disease. Granulocytes 
interact with sickle cells and endothelial cells to release injurious cytokines such as 
IL-1, β and tumour necrosis factor-α (TNFα). These will induce the expression of 
adhesion molecules on the vascular endothelium, and can also cause exposure of the 
underlying extracellular matrix components to which RBCs attach (Madigan & Malik, 
2006). Furthermore, on the vascular side, the activated platelets release 
thrombospondin, which induces the expression of adhesion molecules on the  
endothelium, and can similarly cause the exposure of the underlying extracellular 
matrix components, to which RBCs attach (Madigan & Malik, 2006)). 
The sickling process takes time owing to the fact that deoxy-HbS must assemble 
before polymerization can occur. Usually, transit through the microcirculation is 
completed before this ‘delay time’ elapses, and so sickling does not take place; 
however, with prolonged transit time of RBCs, low O2 tension leads to increased 
deoxy-HbS concentrations and hence sickling will occur (Stuart & Nagel, 2004). 
Role of Anti Oxidants and Free Radicals 
Molecular oxygen has the capacity to form highly reactive metabolites such as 
superoxide anion radical O2∙-, hydrogen peroxide (H2O2), and hydroxyl radical (∙OH). 
These reduced metabolites of oxygen are referred to as reactive oxygen species 
(ROS). Reactive oxygen species can induce oxidative damage to the cell and form a 
very stable structure by extracting electrons from other sources. Superoxide 
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dismulated into H2O2 and oxygen. Hydrogen peroxide has the ability to form the more 
damaging ∙OH, through acombination of the Fenton reaction.  
Fe2+  +  H2O2  →  Fe3+   +  ∙OH  +  OH- 
The inhibition of the mitochondrial electron transport chain activity lead to ROS 
generation, by inducing a leak of electrons from complex I. Generation of ROS result 
from the activation of enzymes such as xanthine oxidase (XO), NADPH oxidase, 
nitric oxide synthase (NOS), cytochrome P450, cyclo-oxygenase, and lipoxygenase. 
All these enzymes can be activated during the repeated cycle of 
hypoxia/reoxygenation or ischemia/reperfusion (Chirico & Pialoux, 2012). 
Major ROS defense mechanisms include enzymatic and nonenzymatic systems. These 
protective mechanisms include the enzymatic antioxidants: superoxide dismutase 
(SOD), catalase, glutathione peroxidase (GPX), and nitric oxide (NO) and the 
nonenzymatic antioxidants: tocopherols, reduced glutathione(GSH), ascorbic acid (A-
HOOH), lipoic acid selenium, riboflavin, zinc, carotenoids, and uric acid (Amer et al., 
2006). 
Unneutralized ROS can target biological molecules such as DNA, lipids, proteins and 
carbohydrates, which result in cell dysfunction or cell death. Although there is 
elevated oxidative stress in SCA, it is effect can be affected by other factors such as 
diet, physical activity, environment, and other comorbid diseases associated with SCA 
(Wood et al., 2008). 
The intracellular polymerization of HbS, during deoxygenation, is the primary 
pathogenetic event in SCA. Polymerization can transform a normal red blood cell 
(RBC) into a dense, inflexible blood cell. The rate of polymerization has been shown 
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in vitro to be correlated with the concentration of HbS and with the cell-free haeme 
released after auto-oxidation (Chirico & Pialoux, 2012). 
The RBC reoxygenation phase is a major source of free radical production in SCA. 
Normal RBCs generate a significant amount of superoxide due to an electron transfer 
between the haeme iron and oxygen. In the presence of oxygen, haeme auto-oxidizes 
inducing methemoglobin and superoxide formation. Although both haemoglobin A 
and HbS blood have a tendency to auto-oxidize into methemoglobin and superoxide, 
haemoglobin A can counter this reaction by forming harmless byproducts; HbS can 
become overwhelmed by the continual source of superoxide and, via its dismutation, 
H2O2. The formation of H2O2, when exposed to methemoglobin, decomposes 
hemoglobin and releases iron. This iron then react with remaining H2O2 to further 
produce ∙OH, the most reactive and harmful of the reactive species.  
Haemoglobin Haplotype and Sickle Cell Phenotype 
Sickle cell disease haplotypes are described as polymorphic restriction of 
endonuclease sites in and around the mutant β-globin gene (Powars & Hiti, 1993). 
Although all the haplotypes have numeric identifiers, they are nevertheless frequently 
designated by the geographic areas in which they were first identified: Senegal, 
Benin, Central African Republic (CAR) or Bantu, Cameroon and Arab-India (or 
Asian) (Alsultan et al., 2014). 
The Senegal haplotype is represented in Senegal and in the Western province of 
Africa above the Niger River, whilst the Benin haplotype were found in Nigeria, 
Benin, and countries in the Bight of Benin. Furthermore, the Central African Republic 
or Bantu haplotype encompasses those haplotypes discovered in the Central African 
Republic and countries in south central Africa. In contrast, the Cameroon haplotype 
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has been found in only one ethnic group in the Cameroons. The Arab-India haplotype 
frequently refers to those haplotypes found in the Persian Gulf and India (Alsultan et 
al., 2014). 
The existence of haplotypes specific to certain regions of the world suggests that the 
mutant β-globin gene arose separately in these locations (Oner et al., 1992). All of 
these areas have been endemic locations of malaria infestation, thus, the high 
incidence of the sickle mutation in these areas is most likely derived from natural 
selection (Carlson et al., 1994 ). Moreover the mutation that produces sickle 
haemoglobin occurs spontaneously at a low rate. Notably, people with sickle cell trait 
are more resistant to malaria than those with normal haemoglobin. Therefore they 
have a better chance of passing the sickle gene to the next generation.  
The haplotype of the sickle mutation has certain effects on the clinical presentation. 
The three common haplotypes in the USA are Senegal, Benin, and Central African 
Republic or Bantu (Hattoni et al., 1989; Powars et al., 1994). Each of these is 
associated with various different degrees of disease severity. For instance, people with 
the Senegal haplotype have a mild clinical course, whilst those with the CAR/Bantu 
haplotype usually have the more severe form of the disease. People with the Benin 
haplotype have an intermediate severity (Powars et al., 1994). In India and the Persian 
Gulf Province, SCA essentially follows a more benign course than it does in Africa 
and USA. The mechanism by which haplotypes influence sickle cell disease severity 
remains unidentified. Individual haplotypes retain varying levels of foetal 
haemoglobin. Patients with the Senegal haplotype, often preserve foetal haemoglobin 
levels of 20% or more. In contrast, patient with the Bantu/CAR haplotype generally 
express the lowest foetal haemoglobin levels and therefore, patients tend to run more 
severe clinical courses. Importantly the Benin haplotype is associated with 
intermediate foetal haemoglobin levels (Powars et al., 1994), which corresponds to its 
intermediate clinical course. With this in mind, there is a contradictory view that the 
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5' promotor region of the, ‘G-gamma’ globin influences foetal haemoglobin level 
(Economou et al., 1991; Powars et al., 1994). Irrespective of the cause, however, the 
observation remains that higher levels of HbF are seen in patients with the Senegal 
haplotype, with clinically milder disease.  
Sickle cell anaemia genes occur in two major areas in Eastern and Southwest Saudi 
Arabia. The gene frequency in the Eastern province of Saudi Arabia varies from 0 - 
0.145 %. In the Western Province the βs-globin gene is linked to the Benin haplotype 
of African origin, whilst the Arab-India haplotype is linked to the Eastern province 
(Daar et al., 2000; Serjeant et al., 2001). The Arab- India haplotype is predominant in 
the Eastern province whilst the Benin haplotype imported from Africa is common in 
the Southwest (Serjeant et al., 2001). The Arab-India haplotype most likely originated 
in the Indus valley Harappa culture and by gene flow was distributed to Saudi Arabia 
particularly to Eastern Province (Stuart & Nagel, 2004).  
Other genetic factors influencing disease severity include α- globin gene deletion and 
the level of haemoglobin F. The α-thalassaemia disease occurs in 50% of the 
population in both areas. Furthermore, high levels of haemoglobin F, which is a 
characteristic of Arab- India haplotype, could explain the milder clinical course in the 
Eastern Province compared to the Southwestern (Serjeant et al., 2001). 
 Sickle cell anaemia leads to clinical manifestation of chronic haemolysis and its 
complications, vascular occlusion, tissue ischemia, bone marrow fat embolisation 
syndromes, susceptibility to infections and end-organ damage. The clinical 
manifestations comprise stroke, retinopathy, a vascular necrosis of bone, priapism, 
splenic infarction or sequestration, renal and, hepatic complications and secondary 
pulmonary hypertension (Steinberg, 1999). Moreover organ damage frequently results 
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from a combination of progressive vasculopathy and acute infarction (Chiang & 
Frenette, 2005). 
 The clinical presentation of sickle cell disease is dominated by either haemolysis or 
vaso-occlusion. Furthermore, pulmonary hypertension, priapism, leg ulceration, and 
non-haemorrhagic stroke are all related to the degree of haemolysis by a similar 
pathophysiology, which is seen in other chronic intravascular haemolytic anaemias 
(Kato et al., 2007) (Figure 1.3).  
Haemolysis, in conjunction with endothelial dysfunction, causes proliferative 
vasculopathy and the deregulation of vasomotor function. High levels of haemolytic 
markers such as reticulocyte count, serum lactate dehydrogenase, plasma 
haemoglobin and arginase, indicate a state of impaired NO bioavailability under 
conditions of low haemoglobin (Madigan & Malik, 2006). 
However, haemolysis plays an insignificant role in the vaso-occlusive complications 
of the disease, including the acute painful episodes, osteonecrosis of bone or the acute 
chest syndrome. Moreover, those patients with SCA with higher haemoglobin levels 
tend to have a higher frequency of vaso-occlusive hyperviscosity related 
complications, linked with the polymerisation of sickle haemoglobin, thereby 
resulting in erythrocyte sickling and adhesion. The prevalence and severity of each of 
these subphenotypes overlap with each other (Alexander et al., 2004). 
1.4 Clinical Features 
The clinical features of SCA are severe haemolytic anaemia punctuated by crisis. The 
symptoms of anaemia are often mild in relation to the measured haemoglobin levels. 
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The clinical expression of HbSS is variable: some patients have an almost normal life, 
free from crisis whilst others develop severe and frequent crisis. 
Types of Crisis 
Painful Vaso-Occlusive Crisis 
Sickle cell disease is a chronic disorder, characterised by acute events that result in a 
shortening of life expectancy. Vaso-occlusion is responsible for the majority of the 
severe complications of SCA. The chief presentations amongst the clinical features of 
SCA are acute episodes of severe pain in the chest, back and abdomen, or extremities, 
lasting for days or weeks. Multiple areas are often involved simultaneously, and 
symmetric involvement of extremities is common. The most serious vaso-occlusive 
crisis are those which affect the brain (strokes occur in 7% of all patients) or spinal 
cord. The painful dactylitis caused by infarcts of small bones of the hands and feet, 
known as ‘hand-foot’ syndrome, may also occur (Hoffbrand et al., 2005). 
Visceral Sequestration Crisis 
This type of crisis is caused by sickling within organs and pooling of blood, often 
associated with severe anaemia. The acute chest syndrome is a frequent and 
sometimes fatal complication affecting approximately 40% of all people with SCA. 
The clinical syndrome is less severe in children. Chest syndrome can occur 
postoperatively and, when recurrent, can lead to chronic respiratory insufficiency. Its 
cardinal features are fever, pleuritic chest pain, referred abdominal pain, cough, lung 
infiltrates and hypoxia. Other sequestration crisis can occur in the liver and the spleen, 
which is typically seen in infants and presents with splenomegaly, falling 
haemoglobin levels and abdominal pain (Telen, 2001). 
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Aplastic Crisis 
Aplastic crisis may be precipitated by parvovirus infection or folate deficiency and are 
characterised by a sudden fall in haemoglobin level and reticulocytes, as the bone 
marrow ceases to respond to anaemia (Telen, 2001). 
Haemolytic Crisis 
This is characterised by an increased rate of haemolysis, which results in a fall in 
haemoglobin level, but a rise in reticulocytes in response to anaemia. 
Hepatic Manifestations in Sickle Cell Anaemia 
Sickle cell hepatopathy encompasses a wide range of hepatic pathologies arising from 
a variety of insults to the liver. The direct manifestations of SCA in the liver relate 
predominantly to vascular occlusion, the complications of multiple transfusions and 
chronic haemolysis. Vascular hepatic occlusion is caused by acute ischaemia, 
sequestration, and cholestasis. The main hepatic complications of multiple 
transfusions include infection with hepatitis B and C and iron overload. The potential 
consequence of chronic haemolysis is the development of pigment stones, with 
consequent cholecystitis and acute and chronic biliary obstruction (Banerjee et al., 
2001).  
Clinical Syndromes 
Acute Sickle hepatic Crisis: Acute sickle hepatic crisis occurs in approximately 10% 
of patients with SCA. Patients commonly present with acute right upper quadrant 
pain, nausea, low-grade fever, tender hepatomegaly, and jaundice. Plasma aspartate 
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transaminase (AST) and alanine transferase levels are usually raised (Oner et al., 
1992). Liver biopsy confirms the diagnosis (Banerjee et al., 2001).  
Hepatic Sequestration Crisis: Hepatic sequestration result in right upper quadrant 
pain, thereby increasing hepatomegaly and a falling haematocrit (Ebert et al., 2010) 
described two cases of hepatic sequestration with little alteration in the liver function 
tests. Exchange transfusion is preferable to partial exchange or additive transfusion in 
such patients. 
Sickle Cell Intrahepatic Cholestasis: This is a disastrous and often fatal condition 
representing a severe variant of sickle hepatic crisis. It occurs owing to widespread 
sickling cells within sinusoids, with hepatic ischemia. Notably, damage in this regard 
is caused by hypoxia of the hepatocytes, with resultant intracanalicular cholestasis. 
The presentation is similar to sickle hepatic crisis, although leukocytosis, striking 
jaundice, bleeding diathesis, and increasing encephalopathy are major differentiating 
features. Plasma alanine, AST, alkaline phosphatase and lactic dehydrogenase levels 
are often markedly elevated (Hoffbrand et al., 2005). The characteristic finding is that 
of very high plasma bilirubin concentrations which is caused by a combination of on-
going haemolysis and intrahepatic cholestasis.  In most cases, the conjugated fraction 
exceeds 50% of the total bilirubin. Bilirubin levels correlate with lactic 
dehydrogenase levels. Moreover, the prolongation of the prothrombin time and partial 
thromboplastin time are common. Hypofibrinogenaemia, thrombocytopenia and lactic 
acidosis may accompany this type of liver failure. Elevations in blood urea, creatinine 
and ammonia are also observed. Importantly, the reversal of this process could be 
achieved through vigorous exchange transfusions and correction of coagulopathy with 
fresh frozen plasma (Banerjee et al., 2001). 
Cholelithiasis in Sickle Cell Anaemia Patients 
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Cholelithiasis is extremely common in patients with SCA, with gall stones being 
present in up to 58% of patients aged between 10 and 65 years. With this in mind, 
elective laparoscopic cholecystectomy should be considered in patients with 
symptomatic gall stones (Al-Mulhim et al., 2002).  
Hepatic Iron Overload in Sickle Cell Patients 
Serum ferritin levels correlate with the number of blood transfusion. High serum 
ferritin occurs during painful vaso-occlusive sickle crisis, and hence steady-state 
ferritin levels provide a better estimate of the degree of iron overload. In this regard, 
iron chelation therapy, with intravenous or subcutaneous desferrioxamine, results in 
increased urinary and biliary excretion of iron and is associated with a significant fall 
in serum ferritin level (Telen, 2001). 
Viral Hepatitis in Sickle Cell Anaemia Patients 
The prevalence of chronic Hepatitis B infection in SCA patients is low (Al-Fawaz & 
Ramia, 1993; Ocak et al., 2006). A relatively high prevalence of Hepatitis C infection 
has been reported (Ocak et al., 2006). The risk of infection has, however, been related 
to the number of units of blood transfused. Patients with acute Hepatitis B have a high 
level of bilirubin, AST and ALT levels (Ocak et al., 2006). Sickle cell anaemia 
patients should receive the Hepatitis B vaccine.  
Renal Complications 
Sickle cell anaemia is associated with numerous renal complications, ranging from 
hyposthenuria to end-stage renal failure. In this regard, the hypoxic, acidotic and 
hypertonic microenvironment of the renal medulla causes the sickling of red blood 
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cells in the vasa recta, consequently leading to infarction of the renal medulla, 
hyposthenuria, haematuria and enuresis. Repeated episodes of hyperchloraemic 
acidosis and enuresis occur in children with papillary necrosis. Renal impairment in 
SCA causes poor urinary concentrating ability, and so plasma osmolarity can arise, 
thereby promoting RBC dehydration, which will further worsen the sickling process. 
Urinary tract infections are usually caused by Escherichia coli and are more common 
in females than in males. Frequent urinary tract infection results in renal infarction. 
Electrolytes imbalance including, impaired potassium excretion, hyperchloraemic 
acidosis and hyperuricaemia have been reported. Hyperuricaemia owing to increased 
bone marrow activity, with consequent enhanced purine metabolism appears to cause 
an acquired defect in the renal tubules. Resultant gout has also been described in a 
few patients (Ballas, 2001; Johnson, 1999). 
Nephrotic syndrome occurs infrequently, either with or without hypertension. 
Microscopic haematuria, proteinuria and hypertension are markers of incipient end 
stage renal failure, the pathologic finding of which is usually glomerulosclerosis. 
Once chronic renal failure becomes apparent, patients require chronic haemodialysis 
and are candidates for kidney transplantation (Ballas, 2001; Johnson, 1999). 
1.5 Pathogenesis of Infections in Sickle Cell Anaemia  
The sickle gene indirectly confers an increased susceptibility to infection, especially 
to certain microbial agents, and at the same time, infection provokes a cascade of 
SCA-specific pathophysiological changes (Booth et al., 2010). Infection is a 
significant contributor to morbidity and mortality in SCA.  
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Impaired Splenic Function 
Splenic dysfunction has a key role to play in the increased susceptibility to certain 
bacterial infections seen in SCA. Normal spleen functions act as a phagocytic filter, 
removing old and damaged cells and blood-borne microorganisms, and accordingly 
producing antibodies. Blood from the splenic artery first traverses the white pulp, 
which contains collections of B and T lymphocytes in follicles and periarteriolar 
lymphatic sheaths. Moreover, the activation of these cells by antigenic material 
enables the initiation and expansion of a specific acquired immune response. 
Subsequently, blood then enters the splenic cords of the red pulp, where cells flow 
over a fine reticular meshwork and pass through fenestrated epithelium to enter the 
venous sinuses. This creates a slow flow, enabling splenic macrophages to remove 
defective RBCs and bacteria and presenting antigen to lymphocytes (Bohnsack & 
Brown, 1986). Some bacteria can be recognized directly by macrophages, but many 
require opsonisation. Opsonisation is the coating of the microbial surface by 
complement components (especially C3b) or other molecules, which subsequently 
interact with receptors on phagocytic cells (Janeway & Travers, 2001). Opsonised 
bacteria are removed efficiently by macrophages in the spleen or liver, whilst poorly 
opsonised bacteria are only cleared by the spleen. Such pathogens include 
encapsulated bacteria in particular Streptococcus pneumoniae and Haemophilus 
influenzae. Their polysaccharide capsule impedes binding complement or prevents 
complement assembled on the cell wall from interacting with macrophage receptors 
(Bohnsack & Brown, 1986). Notably, the clearance of these bacteria requires anti-
polysaccharide IgM antibodies, which facilitate phagocytosis either directly or via 
complement deposition. IgM lies on the surface of memory B cells, which reside in 
the marginal zone of the spleen. These cells persist after an initial infection and 
rapidly produce antibody on subsequent exposures (Bohnsack & Brown, 1986). The 
spleen is the site of synthesis of tuftsin, an immunostimulatory peptide, and properdin, 
which participates in complement activation (William & Corazza, 2007). Individuals 
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with SCA typically suffer from functional hyposplenism or asplenism. The sluggish 
circulation through the spleen, high rates of O2 extraction and local acidosis cause 
deoxygenation of HbS, promote sickling, which leads to the congestion of the 
sinusoids with sickled cells; this can subsequently cause diversion of blood via 
intrasplenic shunts by passing the normal filtering mechanisms. In this regard, 
macrophages engulfing the abnormally shaped cells may become ‘blocked’, thereby 
impairing their phagocytic function. Together these effects produce a hyposplenic 
state which is initially reversible (William & Corazza, 2007). However, over time, 
repeated episodes of sickling and ischaemic damage with progressive sclerosis of 
arterioles lead to multiple infarcts of spleen tissue. Unable to regenerate, the spleen 
becomes scarred and atrophied; culminating in ‘autosplenectomy’, where the organ 
shrinks to a small remnant and the individual is rendered effectively asplenic (Lucas, 
2004). In HbSS, this sequence develops from the age of 6 months through to 3 years 
(William et al., 2007). Hyposplenic and asplenic individuals lack memory B cells, 
thereby suggesting a role for the spleen in their generation or function; as a result, 
they cannot mount a rapid specific response to encapsulated organisms. 
Overwhelming sepsis is the ultimate result of the spread of local infections and the 
loss of the spleen’s filtering function. The main pathogen of concern is Streptococcus 
pneumoniae, although severe and systemic infections with Haemophilus influenzae, 
Neisseria meningitidis, and salmonellae also occur. Prior to preventive measures 
being implemented, children with SCA were 30-600 times more likely to develop 
overwhelming sepsis. Overwhelming sepsis can develop rapidly with no obvious 
primary source of infection, and can consequently result in invasive pneumococcal 
disease (IPD), including pneumonia, meningitis, and septicaemias (Halasa et al., 
2007). Shock, disseminated intravascular coagulation, adrenal haemorrhage and also 
death can occur within 24-48 hours (William et al., 2007). Mortality rate reaches 10% 
from meningitis and up to between 35% and 50% from septicaemias. The risk is more 
common in children, with a reported incidence of 5.8 per 100 in children aged less 
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than 3 years, 1.1 per 100 in those aged 5-9 years, and 0.6 per 100 in those aged over 
10 years, all during the pre-treatment period (Overturf, 2003). 
Defects in Complement Activation 
Despite the modern prophylactic measures, major infections occur mostly in early 
infancy, when the spleen is still partially functional; which suggests additional 
immune deficits (Tamouza et al., 2002). Patients are commonly predisposed to other 
infections, including Escherichia coli urinary tract infection, Mycoplasma 
pneumoniae (M. pneumoniae) or Chlamydophila pneumoniae (C. pneumoniae) 
respiratory infections, and dental infections and cholecystitis caused by anaerobes. 
The complement system involves a large number of plasma proteins which are 
cleaved sequentially by protease enzymes to generate active fragments. These 
function as opsonins or chemo-attractants, and the terminal components can kill 
various pathogens directly through creating pores in their membranes. The cascade 
can then be activated either via the classical pathway, following binding of IgM or 
IgG to surface antigens, or via the alternative pathway, in which C3b interacts directly 
with the pathogen cell surface, subsequently recruiting further downstream 
components (Janeway & Travers, 2001). 
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Deficiencies in Micronutrients 
Zinc is known to be important for immune function. Zinc deficiency is associated 
with lymphopenia, possibly owing to activation of the hypothalamic-pituitary-
adrenocortical axis. Notably, this will subsequently cause chronic glucocorticoid 
production, which stimulates apoptosis of B and T cells in bone marrow and the 
thymus (Fraker et al., 2000). Moreover zinc deficiency has also been linked with 
reduced production of interleukin 2 (IL) a cytokine needed for expansion and 
maintenance of thymocytes and peripheral T cells, reduced natural killer (NK) cell 
lytic activity, thymulin activity, CD4:CD8 ratio, and impaired T helper cell function 
(Prasad et al., 1999). In this regards high protein turnover increases zinc requirements, 
whilst released zinc from haemolysed RBCs is lost via the kidneys owing to renal 
tubular damage which impairs re-absorption. At the same time, poor diet and 
inadequate intestinal absorption could further reduce its level. Zinc deficiency which 
affects 60-70% of patients with SCA, is a contributory factor in susceptibility to 
infection (Prasad, 2002). A study in 21 zinc deficient children from Detroit Medical 
Center suggests that giving supplements increased IL-2 levels, reduced the incidence 
of bacterial infections and further cut hospital admissions (Prasad et al., 1999); 
however, this was not a fully controlled trial, although, if such a simple measure as a 
mineral supplement could improve quality of life, the issue may accordingly warrant 
further exploration. Similar studies have been reported amongst Saudi Patients with 
SCA whereby a significant decrease in serum levels of zinc was found in patients 
compared with controls. In addition zinc supplementation ameliorated some of the 
SCA symptoms and improves the overall quality of life (Hasanato, 2006). 
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Genetic Factors 
Despite sharing the same underlying genetic mutation, the range of severity in the 
phenotype of SCA is striking, with some patients disabled by frequent crisis and long-
term complications whilst others live virtually normal lives. Individuals are also 
differently predisposed to particular pathological manifestations of the disease, which 
suggests that the phenotype is multigenic. Moreover many unlinked genes are 
involved in the underlying pathological processes and variation in alleles at multiple 
loci may modify outcome (Stuart & Nagel, 2004). 
In this regard, polymorphisms in a number of genes involved in the immune response 
have been suggested as a contributing factor to increased susceptibility to infection in 
SCA. Although unlinked to the sickle gene, these variants may coincidentally occur 
with increased frequency in SCA population. Particular HLA-II subtypes have been 
shown to influence infectious complications (Tamouza et al., 2002).  
Certain polymorphisms of the fragment crytallizable receptor (FcR), mannose-binding 
lectin, insulin-like growth factor 1 receptor (IGF1-R), and genes of the transforming 
growth factor β (TGF β)/bone morphogenic protein (BMP) pathway have been 
associated with an increased risk of bacteraemia (Adewoye et al., 2006). In this 
regard, studies also highlight the need for caution in generalising, in terms of immune 
function in SCA; for example, complement activation or neutrophil action, based on 
experiments using small numbers of subjects in localised geographical areas. 
Importantly, observed differences may increase individual risk, but may not be a 
universal feature (Wong et al., 1992).  
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Mechanical Factors 
The pathological effects of SCA can create an environment which supports infection. 
Bone marrow space expands in such a way so as to accommodate the increased 
haematopoiesis to compensate for chronic haemolysis. At the same time, circulation is 
sluggish. Notably, these factors render bone vulnerable to vaso-occlusive episodes 
and infarction. Areas of necrotic bone act as foci for bacterial infection established via 
haematogenous spread (Atkins et al., 1997); therefore, children with SCA are 
predisposed to osteomyelitis. Salmonella species is the commonest agent in SCA 
osteomyelitis, followed by Staphylococcus aureus then Gram-negative enteric 
bacteria (Antonio & Irene, 2005). Edwardsiella tarda is another enterobacterium 
which has been reported with increased incidence in SCA owing to increased gut 
permeability and biliary sludging (Wang et al., 2005). In contrast, Staphylococcus 
aureus is the predominant pathogen for osteomyelitis in children unaffected by SCA. 
Another consequence of microvascular disease is the association with acute chest 
syndrome. With this in mind, several reports in the literature document an association 
between respiratory infections and acute chest syndrome (Neumayr et al., 2003; 
Vichinsky et al., 2000). Sickle cell anaemia carries an increased risk of prolonged and 
severe respiratory infections owing to Mycoplasma, Chlamydia and other pathogens. 
This is particularly true in the case of children with microvascular sequestration, such 
as those with SC haemoglobinopathy. Further evidence is provided by patients with 
SCA, who may be predisposed to certain iatrogenic infections because of therapeutic 
interventions. 
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Transfusion Transmitted Infections  
Blood transfusion is commonly used to treat complications, particularly aplastic crisis 
or splenic sequestration, acute chest syndrome, priapism, or strokes. In the instance of 
stroke, exchange transfusion is used to reduce the proportion of HbS (Win, 2004). 
Increasingly, chronic transfusion therapy is being applied in children in order to 
prevent strokes by keeping HbS levels below 30%. In developed countries, 5-10% of 
children may be involved in a chronic transfusion programme at some point in their 
lives (Dick, 2007). In general, such programmes are potentially associated with an 
increased risk of blood-borne infections, particularly Hepatitis B and C and the human 
immunodeficiency virus (HIV). Although all blood products in developed countries 
are screened for these viruses, standards in other countries may not be so exacting, 
and so early Hepatitis B immunisation is recommended as a preventive measure. 
Other viruses, including cytomegalovirus (CMV) and parvovirus B19, can also be 
transmitted. Although not a problem in immune competent individuals, CMV is a 
significant pathogen in the immune compromised, and so children who are potential 
candidates for bone marrow transplant should receive CMV seronegative blood (Win, 
2004). With this in mind, it is also noteworthy to highlight that patients are also at risk 
of catheter-related infections, particularly those on prolonged courses of parenteral 
antibiotics or with indwelling vascular devices for chronic blood transfusion; this has 
been reported in adults, and seems to be particularly associated with bone infections 
(Zarrouk et al., 2006). 
1.6 The Effect of Infection on Sickle Cell Anaemia 
Infection has long been recognised as one of the most common precipitants of crisis in 
SCA. During infection with any pathogen, changes occur at a cellular level, which 
predispose to crisis. Levels of circulating leukocytes and inflammatory cytokines 
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increase, with an elevated expression of adhesion molecules occurring on both the 
vascular endothelium and leukocytes. Vaso-occlusion, initially assumed to be due to 
passive mechanical blockage by sickled RBCs, is in fact, a complex, dynamic process 
involving active interaction between cell adhesion molecules. Notably, this could 
contribute directly to occlusion, but also acts via slowing transit of RBCs through the 
microvasculature. 
Leukocyte adhesion may ultimately be the initiating event in vaso-occlusive episodes. 
Leukocyte attachment occurs in post-capillary venules the site of leukocyte passage 
into the extra-cellular space. Moreover, patients with severe SCA have increased 
expression of leukocyte adhesion molecules such as Mb2 integrin, L-selectin, and  
CD18 during steady state (Frenette & Atweh, 2007). Leukocytes produce cytokines 
TNF- α and IL-1β induce the expression of VCAM and can cause exposure of the 
underlying extracellular matrix components which attaches to RBCs (Madigan & 
Malik, 2006). In addition, narrowing of the vessel lumen by attached leukocytes may 
enable the accumulation of RBCs, platelets, and further leukocytes, with increasing 
occlusion. Resultant local hypoxia promotes RBC sickling and propagation of the 
blockage, culminating in a crisis.  
In addition, neutrophils, basophils, and monocytes increased during inflammation 
produce cytotoxic proteins such as proteases, collagenase, and elastase and generate 
reactive O2 radicals, which cause oxidative damage. This notably promotes further 
endothelial activation and cell adhesion (Frenette & Atweh, 2007). Importantly, the 
Lutheran blood group glycoprotein (Lu), also known as basal cell adhesion molecule 
(B-CAM) is an adhesion glycoprotein involved in RBC adhesion to endothelium in 
SCA. This cell adhesion to laminin, a major component of the subendothelium, is 
stimulated by epinephrine. Importantly, stress mediates the release of epinephrine, 
which is believed to contribute to vascular occlusion in sickle cell disease (Stuart & 
Nagel, 2004). Furthermore, at inflammatory sites, the sluggish circulation, hypoxia, 
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local acidosis and hypercapnia shift the Hb-oxygen dissociation curve to the right, 
thereby promoting unloading of oxygen from Hb and thus increasing sickling process.  
The Ca2+ sensitive K+ efflux (Gardos channel) is constitutively over expressed in 
SCA, but is further activated by low pH. The resultant K+ and water efflux will lead to 
RBC dehydration. Gardos channel, which is activated by cytokines, chemokines, and 
prostaglandin E2 (PGE2), enhances sickling during infection (Madigan & Malik, 
2006; Stuart & Nagel, 2004). Furthermore, steady state neutrophil count correlates 
with the severity of SCA, and treatment with hydroxyurea, which lowers neutrophil 
numbers, reducing the frequency of painful crisis and hospital admissions (Okpala, 
2004a). In addition, infections can have non-specific effects on the host physiological 
environment, which increase the risk of sickling. Fever with water loss owing to 
sweating, anorexia, and nausea with reduced oral fluid intake, diarrhoea, and vomiting 
all contribute to dehydration.  
Effect of Specific Infections on SCA 
Parvovirus B19 
Parvovirus B19 is a single-stranded DNA virus transmitted by respiratory droplets, 
occurring in outbreaks particularly in late winter and early spring (Servey et al., 
2007). It is a common childhood infection with an incidence of 11.3 per 100 SCA 
patient-years (Servey et al., 2007).  
Moreover, approximately 26% of children are seropositive by age 5, increasing to 
47% aged 10, 64% aged 15, and 73% in adulthood (Smith-Whitley et al., 2004). In 
normal individuals infection is often asymptomatic or otherwise gives mild flu-like 
symptoms, or even may cause erythema infectiosum, characterised by fever, malaise 
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and ‘slapped cheek’ rash on the face, progressing to a generalised maculopapular 
eruption on the trunk and limbs (Servey et al., 2007). Its significance in SCA and 
other haemolytic conditions is that it commonly causes aplastic crisis. Parvovirus B19 
specifically infects erythroid progenitor cells in bone marrow and peripheral blood, 
using surface P-antigen as a receptor, this results in temporary arrest of erythropoiesis, 
lasting 7-10 days.  
In healthy individuals, the normal lifespan of a RBC is 120 days. In the absence of 
erythroid precursors in the bone marrow, erythropoietin production will increase, 
promoting energetic haematopoiesis once bone marrow recovers. However, in SCA, a 
shortened RBC lifespan in addition to transient lack of RBC production, results in a 
severe anaemia (Chisaka et al., 2003). Transient aplastic crisis occurs in 65-80% of 
parvovirus B19 infections. Aplastic crisis is uncommon after the age of 15 years 
(Serjeant et al., 2001). Although most children recover within two weeks, the majority 
require blood transfusion. In this regard, neutropenia has been reported in 18% of 
children and thrombocytopenia in 26.5% with other complications including acute 
splenic or hepatic sequestration at a rate of 19%, acute chest syndrome at 11.8%, 
painful crisis, stroke, nephrotic syndrome, and meningoencephalitis. 
Notably, a similar report on the incidence of aplastic crisis from the Eastern province 
of Saudi Arabia included forty-six patients with SCA all of whom were hospitalised at 
Saudi Aramco-Dhahran Health Center. Evidence of recent human parvovirus 
infection was present in 91% of the cases. Leukopenia was present in 21%, 
neutropenia in 27% and thrombocytopenia in 42% (Mallouh & Qudah, 1993). 
Acute infection can be confirmed by measuring parvovirus B19-specific IgM (89% 
sensitive and 99% specific) or otherwise utilising PCR to amplify viral DNA. This is 
important as the virus is highly contagious, with a secondary attack rate of over 50% 
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amongst other household members (Servey et al., 2007). Siblings with SCA should be 
tested for infection and monitored for the development of aplastic crisis. Following 
infection immunity is life long, thereby leading to calls for the development of a 
vaccine.  
Atypical Bacteria and Acute Chest Syndrome 
The acute chest syndrome (ACS) in SCA is defined as the combination of chest pain, 
dyspnoea, fever, and pulmonary infiltrates on chest X-ray (Dick, 2007). It affects 15-
43% of patients, particularly in early childhood. Moreover, acute chest syndrome is 
responsible for 25% of deaths and is the second most common cause of hospital 
admission (Castro et al., 1994; Platt et al., 1994). Various processes can precipitate 
the condition, including infection, pulmonary fat embolism and hypoventilation, all of 
which could arise from thoracic bony crisis or post surgically or secondary to 
excessive narcotic analgesia. The unifying end result is sickling and vaso-occlusion in 
the small vessels of the lung, causing local ischaemia and sometimes infarction. The 
ventilation-perfusion mismatch causes systemic hypoxia, predisposing to further 
sickling and vascular occlusion in a vicious cycle ending by right heart failure 
(Siddiqui & Ahmed, 2003). In a large multicentre study, the cause of ACS was found 
in 38% of cases.  Moreover, infection was identified in a third of patients. The most 
prevalent infectious agents were Chlamydia pneumoniae (14% of all patients) and 
Mycoplasma pneumoniae (9%), the latter of which was identified more in younger 
patients (Vichinsky et al., 2000). Although isolation does not confirm causation, the 
inflammatory response to lung infection would nevertheless seem likely to provoke 
leukocyte and RBC adhesion and intravascular sickling. Patients with SCA in the 
Eastern Province of Saudi Arabia suffers less severe acute chest syndrome than those 
with African haplotypes (Alabdulaali, 2007).  
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Malaria 
The relationship between malaria and SCA is an interesting one. The persistence of 
the sickle mutation at such high frequency in African populations in spite of the 
severity of SCA has been attributed to the fact that heterozygous sickle trait confers 
protection against severe and life threatening malaria particularly cerebral malaria 
caused by Plasmodium falciparum. The presence of HbS is associated with reduced 
parasitic invasion of erythrocytes, impaired multiplication, and accelerated clearance 
of parasites by the spleen; however infected RBC becomes hypoxic, thereby 
provoking sickling and splenic filtration of infected cells (Makani et al., 2007).  
A similar situation is recognized in Saudi Arabia, where both malaria and SCA could 
coexist. Abudulhadi, 2007 confirms that the heterozygous sickle trait as being 
associated with reduced parasitic erythrocytes invasion and a mild clinical course of 
malaria infection; this occurs owing to alterations in binding of the sickled erythrocyte 
to the peripheral blood mononuclear cells and cytoadherence.  
It might be assumed that homozygous SCA would confer greater resistance to 
malaria; however, the co-existence of the two is associated with increased mortality 
and morbidity, with the malaria being the most common precipitating cause of crisis 
in endemic countries (Oniyangi & Omari, 2006). Among children with malarial and 
SCA, 8.7% die and 66% develop severe anaemia. (Ambe et al., 2001). 
In normal individuals, infected red cells adhere to the capillary endothelium causing 
obstruction. The metabolic activity of parasites within RBCs causes hypoxia, acidosis, 
and hence sickling (Onwubalili, 1983). In SCA patients, the deleterious effects of this 
are magnified; the spleen plays an important role in the control of malaria, thereby 
removing damaged and parasitised RBCs from the circulation, ‘pitting’ infected cells, 
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and generating specific B and T cell responses. Splenectomised individuals with 
Plasmodium falciparum have reduced clearance of parasitised RBCs, but it remains 
unclear as to whether or not they suffer more severe malarial symptoms (Engwerda et 
al., 2005). 
Malaria causes anaemia via a number of mechanisms (Menendez et al., 2000). 
Accordingly haemolysis of infected RBCs occur as merozoites emerge after 
multiplying, whilst haemolysis of non-infected cells occurs owing to the production of 
auto-antibodies against RBC surface molecules. Macrophages phagocytose both 
infected and noninfected cells worsening the anaemia. Malaria can also cause 
dyserythropoiesis and splenic sequestration of RBCs particularly in young children 
who have not undergone autosplenectomy is a contributing factors. Furthermore, 
recurrent haemolysis can produce folate deficiency anaemia. In one Nigerian centre, 
hyperhaemolytic crisis was found to be the most common cause of severe anaemia in 
children (Juwah et al., 2004). 
Malaria is therefore a significant pathogen in SCA, and long-term prophylaxis has 
been highlighted as lowering the incidence of severe anaemia and the number of 
hospital admissions and crisis, as well as reducing overall mortality (Oniyangi & 
Omari, 2006). With this in mind, Bashawri et al., (2001) report in a study in the South 
Western part of Saudi Arabia that Plasmodium falciparum is the most common 
species amongst Saudis (83%) (Bashawri et al., 2001). The frequent clinical signs are 
splenomegaly and jaundice; anaemia and thrombocytopenia are the common 
haematological laboratory findings. 
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Human Immunodeficiency Virus and Sickle Cell Anaemia 
Trivial information is available regarding the impact of coexistent HIV infection and 
SCA. These two conditions can present unique challenge particularly in Africa where 
the incidence of both conditions is highest and resources are scarce. In a retrospective 
study in the USA, hospital discharges of children with both HIV and SCA over a 10-
year period (1994-2003) were analysed (Kourtis et al., 2007). Accordingly, it was 
found that children with both conditions are at increased risk of bacterial infection and 
sepsis and the average hospital stay is longer. Pneumococcal infection risk is high 
amongst HIV-infected adults with SCA (Godeau et al., 1992). Moreover, a high 
frequency of long-term non-progressor patients with HIV and SCA may suggest that 
SCA attenuates the clinical progression of the HIV virus (Bagasra et al., 1998). In 
Saudi Arabia, a study conducted by Madani et al., (2004) notes that the number of 
HIV cases is limited, with heterosexual contact being the main mode of transmission 
(Madani et al., 2004). Preventive strategies include prevention of non-marital sex and 
intravenous drug use.  
Prevention of Infection in SCA 
Infection can lead to a range of complications in SCA which are not readily reversed 
simply by treating the infection. For this particular reason, prevention is the key 
strategy in the management. Interventions during the last 20 years have dramatically 
reduced mortality, especially in children, and the recommendations continue to evolve 
(Booth et al., 2010). 
Simple general measures are important when reducing the risk of infection, though 
the aim is to ensure as normal a lifestyle as possible (Atkins et al., 1997). 
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Nutritional supplementation with zinc has been reported to reduce infection risk 
(Prasad et al., 1999), improve growth rates in children with SCA in Nigeria, and 
improve skeletal and sexual maturation (Zemel et al., 2002). Parents are therefore 
encouraged to monitor their children closely at home and to accordingly seek advice 
if they have a fever or respiratory symptoms, whilst maintaining good hydration. 
Notably, there should be a low threshold for the use of antibiotics in ill children with 
SCA, particularly in the presence of chest signs or symptoms, which may herald ACS. 
Antibiotic Prophylaxis 
Pneumococcal infection is a major threat to patients with SCA. The first presentation 
of the infection may be with sudden death owing to overwhelming sepsis. The first 
major pneumococcal infection breakthrough came in 1986 with the pivotal PROPS 
trial, which showed that prophylactic oral penicillin reduced the risk of IPD incidence 
from 9.8/100 patient-years, to 1.2/100 in children aged less than 3 years (Gaston et 
al., 1986). This inexpensive, simple and safe intervention was rapidly implemented.  
Current recommendations state that oral penicillin V should be commenced at the age 
of 6 months, when protective levels of foetal haemoglobin start to decline and splenic 
hypo function begins to develop. The duration of the prophylaxis remains 
controversial. Since the risk of IPD declines markedly with age, it may be possible to 
modify or stop prophylaxis without compromising the outcome. Importantly, the 
PROPSII trial evaluated the consequences of discontinuing penicillin at 5 years and 
found no significant difference in the incidence of infection between the penicillin and 
control groups, thereby suggesting no added advantage (Falletta et al., 1995). 
However, most of guidelines for asplenic individuals still recommend that penicillin 
prophylaxis be continued lifelong (Davies et al., 2002). 
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Long-term penicillin prophylaxis is not without hazards. Prolonged antibiotic use can 
promote the development of resistant strains, and so the continuation with lower 
pneumococcal infection must be balanced against the danger that resistant organisms 
pose to the whole population (Hirst & Owusu-Ofori, 2002). With this in mind, studies 
by Reynolds et al., (2004) and Alexander et al., (2002) state that 9% of Streptococcus 
pneumoniae isolates from the general population were resistant to penicillin as 
compared with 25% of isolates from children with SCA (Alexander et al., 2002; 
Reynolds et al., 2004). 
Compliance is a major issue in any long-term therapy. One study of children in New 
York found that patient reporting compliance with penicillin prophylaxis was 67.5%, 
but when compliance was measured objectively with a urine assay, the figure was 
43.1%. In this regard, the subgroup of less than 5 years, in whom prophylaxis is most 
important, shows better adherence (61%) (Teach et al., 1998). Moreover similar 
results have been found in British children (Elliott et al., 2001).  
Vaccination 
Vaccination is a basic medical strategy in the prevention of infection. There are ninety 
serotypes of pneumococcal bacteria, which vary in the molecular composition of their 
capsular polysaccharide. The first pneumococcal vaccine produced immunity via a T 
cell independent effect, thereby triggering B cells in the splenic marginal zone to 
secrete antibodies (William et al., 2007).  
Early uncontrolled studies used a vaccine containing 14 antigens and produced a 50% 
reduction in IPD (Overturf, 2003), therefore, the vaccine became widely accepted. 
The current vaccine (Pneumovax, PPS-23) comprises 23 purified antigens, which 
should protect against 75% of IPD, with an added 14% prevented via cross-protection 
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(Overturf, 2002). Adamkiewicz et al., (2003) reported a fifty percent reduction in IPD 
when PPS-23 with penicillin. Since the effectiveness of the vaccine diminishes over 
time, a booster dose is required every 5 years (Adamkiewicz et al., 2003).  
Unfortunately, however, many polysaccharides, especially those from the strains 
causing infections, are either not immunogenic in children under 2 years or otherwise 
produce only a minimal antibody response with a lack of immunological memory 
(Overturf, 2002). This has prompted the search for an alternative. 
The polysaccharide-protein conjugate vaccine (PCV) binds capsular polysaccharides 
to protein in order to increase their immunogenicity. This does induce an effective 
response in infants under 2 years (Overturf, 2002). Moreover prevenar vaccine, a 7-
valent PCV, is licensed for use in Europe and the USA and includes serotypes 
responsible for approximately 70% of the infections. Importantly, studies suggest that 
this vaccine would also cover 77% of isolates of resistant strains, which would avert 
prophylaxis failure and may ultimately help to reduce the frequency of such strains 
(Adamkiewicz et al., 2003). 
The routine immunisation of children with PCV-7 began in the USA in 2000 and in 
the UK in 2006. Multiple doses are required for the most effective response, which 
could be a limiting factor for the full vaccination protocol. The limited supply 
problem was defeated in the USA by 2005 (Nuorti et al., 2008). With this in mind 
early analysis of the effects in patients with SCA have demonstrated very encouraging 
results. In Tennessee, for example, rates of IPD fell by 90.8% in children under 2 
years and 93.4% in children aged less than 5 years. This brought the incidence to only 
6.5 times higher than in unaffected children (Halasa et al., 2007). In the UK, uptake in 
the first year was 6%- still somewhat lower than that for other routine childhood 
immunisations (Salisbury et al., 2006). Children were advised to receive the PPS-23 
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vaccine every 2 years owing to the fact that they remain at high risk for developing 
IPD (Overturf, 2002). Penicillin prophylaxis is still required, in part because all trials 
included antibiotic prophylaxis; it also provides protection against non-PCV-7 
pneumococcal strains. In Africa, pneumococcal prophylaxis programme is 
recommended, although the high cost remains an obstacle to the public health care 
planners (Kizito et al., 2007). 
Other important vaccines include Haemophilus influenzae (Hib), Neisseria 
meningitidis, hepatitis B, and influenza. Children travelling to endemic areas should 
be offered meningitis A and C vaccinations and malaria prophylaxis. Influenza 
infection can precipitate crisis and predisposes to bacterial pneumonia; therefore, 
vaccination is preferred (Dick, 2007; Salisbury et al., 2006). Moreover, 
Pneumococcal, Haemophilus influenza and meningococcal vaccinations are effective 
at reducing infection rate. Hepatitis B vaccine should also be given (Castro, 1999). 
In Saudi Arabia a study was conducted by El-Hazmi et al., (1990) which concluded 
that pneumococcal vaccination and penicillin prophylaxis play a significant role in 
decreasing the morbidity and increasing the crisis- free interval in SCD patients (El-
Hazmi et al., 1990). Another contradictory report by Pejaver et al., (1995) has shown 
that the pneumococcal vaccine and prophylactic oral penicillin had no effect on the 
frequency of hospital admissions rate of SCA patients per year (Pejaver et al., 1995). 
Moreover, the Pneumococcal vaccination programme is still not part of the routine 
guidlines for managing patients with SCA; however, Haemophilias influenzae (Hib) 
vaccine is part of routine immunisation program (Al-Jam'a et al., 2000). 
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1.7 The Role of Phagocytes in Sickle Cell Anaemia 
Neutrophils and monocytes are the main phagocytic cells in the blood which are 
produced in the bone marrow and migrate to the blood stream particularly to the sites 
of infection (Hoffbrand et al., 2006). Neutrophils make a one-way trip but monocytes 
differentiate into macrophages and may recirculate, to act as antigen-presenting cells 
(APCs). Importantly they interplay a regulatory role between the innate and adaptive 
immune system (Takeshi & Shin, 2003). 
Importantly, the endothelium expresses adhesion molecules which are recognised by 
receptors on activated phagocytes which direct cell traffic to these areas. This process 
has been described in patients with SCA who have been found to exhibit interactions 
between sickle red blood cells, leukocytes and endothelial cells via adhesion 
molecules (AbouGhalia et al., 2010; Makis et al., 2000; Roitt et al., 2002).  
Inflammatory reactions have three major components, the increased blood supply and 
capillary permeability, followed by leukocytes migration. The local hyperaemia 
brings leukocytes and serum molecules (antibody and complement) to the affected 
site. Capillary permeability also increases allowing secretion of the serum proteins to 
control the infection. Finally, there is increased migration of leukocytes into the 
tissue. 
Patterns of Leukocyte Migration 
Leukocyte migration is a complex process which depends on the inflammatory cells 
involved, their state of activation and how they interact with endothelium in different 
vascular beds throughout the body (AbouGhalia et al., 2010; Robinson & Babcock, 
1998). Importantly, this is controlled by adhesion molecules, on the migrating cells 
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which interact with the endothelium, tissue cells, the extra cellular matrix, and soluble 
signalling molecules such as chemokines. Chemokines are small pro-inflammatory 
chemotactic cytokines which mediate inflammation by activation of integrin-mediated 
leukocyte adhesion to the vascular endothelium (Roitt et al., 2002). In addition, the 
surface charge of the interacting cells, the haemodynamic shear force in the vascular 
bed and the expression of adhesion molecules on both the leukocytes and the 
endothelium regulate leukocytes migration. The venules provide the perfect 
environment for leukocytes migration, where the surface charge is lowest, 
haemodynamic shear is low and adhesion molecules are expressed (Roitt et al., 2002) 
(Figure  1.4).  
Notably, the first stage of leukocyte migration is the rolling of circulating leukocytes 
on the endothelial surface, the process is known as tethering. Subsequently, triggering 
occurs which indicates that the arrested leukocytes respond to cytokines and 
endothelial CAM. Once the binding between leukocytes and CAM takes place, the 
migration will start and this is known as latching and activation. Moreover, leukocytes 
move either between or through the endothelial cells towards the site of infection 
(Figure  1.5).  
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Figure  1.4 Leukocyte migration in the blood vesels from high to low shear force, with the 
expression of adhesion molecules. Adapted from (Roitt et al., 2002).  
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Figure  1.5 Three-step model of leukocytes adhesion. Tethering: binding and adhesion of 
leukocyte to aendothelium; Triggering: synthesis of adhesion molecules;  Latching: by CR3/LFA-
1 and ICAM-1. Adapted from (Roitt et al., 2002). 
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1.8 Intercellular Adhesion Molecules  
Intercellular adhesion molecules are membrane-bound proteins, which allow one cell 
to intermingle with another. These molecules are trans-membrane proteins which are 
connected to the cell cytoskeleton. As the cell moves, it uses them to gain traction on 
other cells, or on the extracellular matrix. Moreover cell adhesion molecules are 
expressed on both leukocytes and vascular endothelial cells. Adhesion molecules have 
the capability to bind more than one ligand by increasing the numbers of adhesion 
molecules on the surface or by otherwise altering their affinity. Importantly, the level 
of expression can be modified through increasing the synthesis and transporting of 
new molecules, or otherwise by directing the intracellular stores to the cell surface 
following cellular activation (Roitt et al., 2002). Other mechanisms include increased 
affinity, such as leukocyte factor activation (LFA-1) following cell activation. 
Furthermore, reorganisation of adhesion molecules on the cell surface may result in 
the formation of high avidity patches (Figure  1.6).  
The vascular endothelium expresses the immunologic supergene family comprising 
the cellular adhesion molecules ICAM-1, ICAM-2, VCAM -1 and MAdCAM-1 
(mucosal adhesion molecules -1) (Figure  1.7). 
There is a strong positive correlation between the role of cell adhesion molecules and 
pathophysiology of vascular occlusion which plays a major role in the disease severity 
in patients with SCA (Kutlar & Embury, 2014). 
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Figure  1.6 Modulation of leukocyte adhesion. Leukocyte binding to endothelium could become 
enhanced in four ways. (1). Many cells hold stores of adhesion molecules that can rapidly move to 
the cell surface. (2). Endothelial cells at the sites of inflammation may synthesize new adhesion 
molecules. (3) Molecules such as LFA-1 can increase their affinity following cell activation. (4). 
Reorganisation of adhesion molecules on the cell surface may result in the formation of high 
avidity patches. Adapted from (Roitt et al., 2002). 
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Figure  1.7 The endothelium cell expresses the adhesion molecules. LFA-1 and CR3: leukocyte 
factor activation – 1 and control register number 3; ICAM-1: intracellular adhesion molecule-1; 
ICAM-2: intracellular adhesion molecule-2; VLA-4 (LPAM-1): very late antigen-4; VCAM-1: 
vascular cellular adhesion molecule-1; Mad CAM-1: mucosal adhesion cell molecule-1. Adapted 
from (Roitt et al., 2002). 
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Role of Integrins and Selectins in Leukocyte Interaction  
Selectins and integrins are a group of transmembrane cell adhesion molecules present 
in many cells including leukocytes. Selectins consist of E-selectin, P-selectin and L-
selectin (Figure  1.8). Furthermore integrins consist of two non-covalent bound 
polypeptides (α and β). They fall into three main subfamilies depending on whether 
they contain β1, β2 or β3 chain. The β1 integrins are involved in cell binding to the 
extracellular matrix, whilst the β2 are implicated in leukocytes adhesion to 
endothelium, and β3 integrins are involved in the interactions of platelets and 
neutrophils at inflammatory sites of vascular damage (Janeway & Travers, 2001; Roitt 
et al., 2002). 
Soluble E-selectin and P-selectin 
The adhesion molecules are involved in the pathophysiology of SCA and can be 
measured in the peripheral blood during steady state and vaso-occlusive crisis. High 
levels of adhesion molecules such as soluble E-selectin and P-selectin (sE- selectin 
and sP-selectin) have been found in the sera of patients with SCA (Matsui et al., 
2002). Notably, various different levels of sE-selectin, and sP-selectin, have been 
reported in patients with SCA in different parts of the world; however, little 
information exists regarding Arab countries including Saudi Arabia.  
E-selectin  
E-selectin (Endothelial Leukocyte Adhesion Molecule-1), (ELAM-1), also known as 
CD62E, is an 115kDa, type I transmembrane glycoprotein expressed on endothelial 
cells following the activation by inflammatory cytokines (such as IL-1β or TNF-α) or 
endotoxins. Cell-surface E-selectin is a major extra- cellular adhesion molecule which 
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regulates binding and rolling of leukocytes to the endothelium. This is an essential 
step in the extravasation of leukocytes from the blood stream to the site of 
inflammation, thereby playing a key role in localised inflammatory response 
(AbouGhalia et al., 2010; Simon, 2008). 
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Figure  1.8 Structures of selectins. Adapted from (Roitt et al., 2002). 
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The extra cellular part of E-selectin includes a calcium-dependent C2-type lectin 
domain, an epidermal growth factor (EGF) domain, and six repeats of a complement-
regulatory-protein-like sequence (Figure  1.9). E-selectin binds sialyl Lewis X, a sialic 
acid-galactose-N-acetylglucosamine-fructose tetrasaccharide, although the actual 
recognition is considered to be for a specific presentation of those glycosyl units 
specific for glycoprotein (Varki et al., 2008). 
Soluble E-selectin (sE-selectin) is found in the blood of healthy individuals probably 
arising from the proteolytic cleavage of the surface-expressed molecule. Elevated 
levels of sE-selectin in serum have been reported in a variety of pathological 
conditions including SCA. Patients with SCA usually have high levels of circulating 
endothelial cells in the steady state condition, with further increments during vaso- 
occlusive crisis (Ataga & Key, 2007). High levels of circulating ICAM-1, VCAM-1, 
and E-selectin have been found in the blood of patients with acute painful crisis 
(Ataga & Key, 2007; Pathare et al., 2003). 
P-selectin 
P-selectin (GMP-140, LECAM-3, PADGEM, CD62, CD62P) is a member of the 
selectin family of cell surface molecules. It comprises an NH2-terminal lectin type C 
domain, an EGF-like domain; nine complement control domains, a transmembrane 
domain, and a short cytoplasmic domain (Figure  1.9). P-selectin is found 
constitutively in a pre-formed state in the Weibel-Palade bodies of endothelial cells 
and also in the alpha granules of platelets. It is mobilised to the cells within minutes in 
response to a variety of inflammatory conditions or thrombogenic agents. The 
mobilised P-selectin is apparently present on the cell surface for few minutes, after 
which it is recycled to intracellular compartments. The molecular weight predicted 
from the cDNA for P-selectin is approximately 86,000Da.  
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Figure  1.9 Overall domain structures of P-selectin, E-selectin, L-selectin and (P-selectin 
glycoprotein ligand 1(PSGL-1). Adapted from (Mei et al., 1997). 
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The tetrasaccharide sialyl Lewisx (sLWx) has been identified as a ligand for both P- 
and E-selectin and can bind sLex and sLea under appropriate conditions (Figure  1.10). 
P-selectin plays a critical role in the migration of lymphocytes into tissues; it also 
plays a role in the adhesion of myeloid cells, B cells and a subset of T cells to 
activated endothelium. It is also involved in the adhesion of platelets to monocytes 
and neutrophils, thereby playing a central role in the tethering, rolling, and firm 
adhesion of leukocytes to activated endothelial cells. The adhesion of leukocytes to 
the endothelium is initiated by weak interactions, which produce a characteristic 
‘rolling’ motion of the leukocytes and neutrophils on the endothelial surface. P-
selectin in cooperation with L-selectin mediates the initial interactions. Importantly, 
stronger interaction involving E-selectin follow the initial interactions, thereby 
eventually leading to extravasation through the blood vessel walls into lymphoid 
tissues and accordingly to sites of inflammation (Figure  1.11).   
Soluble P-selectin has been found in the plasma of normal individuals at 
concentrations between 36 ng/ml and 250 ng/ml (Mei et al., 1997). Blann et al., 
(2008) reported that sP-selectin level has been elevated in a variety of pathological 
conditions such as haemolytic- uremic syndrome, adult respiratory distress syndrome 
and disseminated intra vascular coagulation (Blann et al., 2008).  
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Figure  1.10 Adhesive interactions between SS red blood cells, plasma proteins, and components 
of the endothelium. FBN: fibronectin; TSP: thrombospondin; ULvWF: ultra-large von 
Willebrand factor; ECM: extracellular matrix; LAM: laminin. Adapted from (Telen, 2007). 
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Figure  1.11 Tethering of circulating leukocytes to activated endothelium via interactions between 
selectins and their ligand. Adapted from (Spertini, 1997)). 
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Soluble P-selectin participates in the adhesion of sickle red blood cells to endothelial 
cells in the steady state condition and in acute painful crisis. At the site of vascular 
injury thrombin stimulates endothelial cells and P-selectin is then rapidly released 
from Weibel-Palade bodies to the luminal surface of the cells. Thrombin, histamine 
agonists, hypoxia and reperfusion have been proven to induce the expression of P-
selectin on human endothelial cell surfaces (Matsui et al., 2002). Patients with SCA 
during the acute painful crisis have abnormal presence of circulating endothelial cell 
adhesion molecules such as ICAM-1, VCAM-1, and sE-selectin in their plasma 
(Pathare et al., 2003; Shiu et al., 2000). In conclusion, sP-selectin is found to be 
proinflammatory and prothrombogenic mediator in patients with SCA (Wood et al., 
2004).  
P-selectin also reportedly binds selectively to a 160 kDa glycoprotein present on 
human myeloid cells termed sP-selectin glycoprotein ligand-1 P-SGL-1. Soluble P-
selectin mediated rolling of leukocytes can be completely inhibited by a monoclonal 
antibody specific for PSGL-1. 
1.9 Treatment 
Patients with SCA should avoid factors known to precipitate crisis, especially 
dehydration, hypoxia, infections and stasis of circulation. Good general nutrition, 
supplemented with folic acid and proper hygiene are all required. 
Treatment of Painful Episodes 
Painful episodes are sometimes triggered by infection, extreme temperatures or 
physical or emotional stress; more often, however, they are unprovoked and begin 
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with little warning. Patients with severe pain should be given an opiate parenterally at 
frequent, fixed intervals until the pain has diminished. Then the dose of opiate can be 
tapered and stopped and oral analgesic therapy instituted using paracetamol and/or 
non-steroidal anti-inflammatory drugs (Castro, 1999; Hoffbrand et al., 2006). 
Treatment of Anaemia 
Blood transfusions are not needed for the usual anaemia or for painful episodes 
associated with SCA. Notably, the urgent replacement of blood is often required for 
sudden severe anaemia occurring in children, such as when blood is sequestered in an 
enlarged spleen or when parvovirus B19 infection triggers a transient aplastic crisis. 
Hypoxia accompanying the acute chest syndrome necessitates transfusion and oxygen 
treatment. Moreover, clinical trials have evaluated the efficacy of transfusion in stroke 
related to SCA. Repeated transfusion reduces the risk of recurrent stroke in children 
with sickle cell anaemia (Dacie & Lewis, 1991; Telen, 2001).  
Notably, approximately 50% of children with SCA and stroke, who do not receive 
transfusions, experience recurrent stroke within three years, as compared with 10% of 
those who received transfusions (Adams et al., 1998; Adams et al., 1992). The aim of 
transfusion is to reduce the HbS concentration rapidly to less than 30% of total 
haemoglobin concentration and to accordingly maintain this percentage for 3-5 years. 
Exchange transfusion, either by manual or more often by an apheresis technique, is 
the treatment of choice in the acute phase (Telen, 2001). A two-year trial has 
investigated the use of prophylactic transfusion in SCA children from 2-16 years of 
age who were screened by transcranial Doppler ultrasonography (TCD) to measure 
cerebrovascular blood flow. Patients with persistently elevated TCD signals are at an 
ongoing stroke risk, which calls for blood transfusion (Kwiatkowski et al., 2006; Lee 
et al., 2006). 
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For patients undergoing general anaesthesia, preoperative top up transfusion, aiming 
at increasing the haematocrit to approximately 30%, prevents postoperative 
complications. This was associated with reduced transfusion-related complications by 
50% (Adedeji et al., 2001). 
Hydroxyurea 
Pharmacokinetics: Hydroxyurea is an analogue of urea which inhibits DNA synthesis 
in the S-phase through the inhibition of ribonucleotides reductase enzyme, resulting in 
depletion of deoxynucleoside triphosphate pool (Edward, 2004; Orah & Platt, 2008). 
The drug is specific for the S phase of the cell cycle and causes cells to arrest at the 
G1- S interface (Cababres & Chabner, 1996; Orah & Platt, 2008). 
Hydroxyurea was found to cause leukopoenia, anaemia and megaloblastic changes in 
the bone marrow. It also exhibits antineoplastic activity against sarcoma. Previously it 
was thought that haemoglobin S polymerization helped in the entrapment of sickled, 
poorly deformable erythrocytes that mechanically blocked small calibre vessels. It 
was later recognized that these damaged erythrocytes alone are not sufficient to 
produce the vaso-occlusion in larger vessels. Therapeutic approaches to sickle cell 
anaemia focused on trials to reduce intracellular HbS polymerization by altering the 
haemoglobin molecules (Noguchi et al., 1993 ).   
Absorption and Excretion: In humans, hydroxyurea administered orally is absorbed 
from the gastrointestinal tract, and peak plasma concentrations are achieved 1-2 hours 
after a dose of 15-30 mg per kilogram of body weight. Notably, the plasma half-life is 
approximately 2 hours, and has almost 100% oral bioavailability. Moreover, 
hydroxyurea has the ability to cross the blood-brain barrier (Cababres & Chabner, 
1996). 
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Approximately 80% of the drug is recovered in the urine within 12 hours following 
oral administration (Orah & Platt, 2008). Moreover, plasma and urine hydroxyurea 
levels can be measured using high performance liquid chromatography (HPLC) 
techniques (Bachir et al., 2007). 
Effect of Hydroxyurea therapy on cell adhesion molecules: Hydroxyurea has a 
potential effect on erythrocyte and leukocytes in patients with SCA. Moreover, it 
reduces the frequency and severity of acute vaso-occlusive crisis by decreasing 
erythrocyte cell adhesion receptors (Gambero et al., 2007; Telen, 2007). Notably, 
sickle erythrocytes were shown to be abnormally adherents to extra cellular matrix 
proteins, thrombospondin (TSP), laminin, and fibronectin. Hydroxyurea was found to 
down regulate their interactions (Gambero et al., 2007; Johnson & Telen, 2008; 
Telen, 2007). Moreover, Covas et al., (2004) have shown that hydroxyurea decreases 
both erythrocyte HbS level as well as the reticulocyte adhesion receptor expression 
(Covas et al., 2004). The sickled reticulocyte expression of VLA-4 and CD 36 was 
measured both before and following hydroxyurea treatment using flow cytometry. 
Notably, after hydroxyurea treatment  both values were reduced, supporting a role for 
hydroxyurea in decreasing the frequency of acute VOC and eventually reducing 
frequent hospitalisation, morbidity and mortality (Telen, 2007; Wang, 2007).  
Furthermore, the interactions between the red blood cells and leukocytes are inhibited 
by the effect of hydroxyurea; this reduces the leukocyte count and minimises the 
activation and adhesion of sickle leukocytes, particularly neutrophils and monocytes 
(Finnegan et al., 2007). Hydroxyurea was also found to normalise L-selectin and H2O2 
in patients with SCA (Benkerrou et al., 2002). In addition, hydroxyurea provides a 
fundamental therapeutic approach to shift haemoglobin production from sickle to 
foetal haemoglobin (Orah & Platt, 2008), decreases haemoglobin polymerisation, 
sickling and haemolysis, accordingly reduces the need for blood transfusions 
(Gambero et al., 2007; Johnson & Telen, 2008).  
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Finally, hydroxyurea metabolites restore NO bioavailability, thereby leading to 
normal vascular tone (Okpala, 2004a; Orah & Platt, 2008) and thus reducing the 
incidence and severity of the VOC.  
With this in mind, the study will fucose on the role of the above mechanisms with 
specific emphasis on the Saudi Arabian population. The literature review has shown 
few studies which thus far have focused specifically on this aspect. 
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Aims 
The overall aims of this study were: 
• To determine the incidence and characteristics of infection in sickle cell anaemia 
patients in acute vaso-occlusive crisis.  
• To evaluate leukocyte phagocytic function in neutrophils and monocytes, of Saudi 
and non-Saudi sickle cell anaemia patients, in steady state and comparing them 
with normal control subjects.  
• To assess any gender related difference in leukocyte phagocytic function, in Saudi 
and non-Saudi sickle cell anaemia patients in steady state; and in normal control 
subjects. 
• To evaluate characteristics of leukocytes by immunophenotyping, using flow 
cytometry in Saudi and non-Saudi sickle cell anaemia patients, both in steady state 
and in vaso-occlusive crisis. Findings were compared to normal control subjects.   
• To determine the difference in the levels of the adhesion molecules, "sE-selectin and 
sP-selectin" between Saudi and non-Saudi sickle cell anaemia patients in both 
steady state and in acute vaso-occlusive crisis; and compared to normal control 
subjects.   
  
 
 
CHAPTER 2  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Selection of Subjects 
The population study comprised of sickle cell anaemia patients (SCA) at both phases 
(the acute vaso-occlusive crisis and the steady state), and normal healthy control 
subjects with normal haemoglobin (HbAA). The status of selected patients and 
control subjects was confirmed through the utilizing of sickle solubility test and 
cellulose acetate electrophoresis. These tests were performed by technicians in the 
Department of Haematology at the King Abdulaziz University Hospital, (KAUH), 
Jeddah, Saudi Arabia.   
Patients in Vaso-Occlusive Crisis 
Subjects in this group were sickle cell anemia patient, with sickle haemoglobin 
(HbSS) and clinically diagnosed as having acute vaso-occlusive crisis (VOC). They 
were experiencing an episode of acute pain in the abdomen and/or the extremities 
with signs of increased haemolysis, usually presented to emergency room at KAUH.  
The sickle cell anaemia patients with acute VOC aged 18-45 years old took part in 
this study. The age of SCA in steady state ranged between 15 and 45 years. The age 
of normal control subjects ranged between 18 and 45 years.  
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Patients in Steady State 
Subjects in this group were HbSS patients, in haematology clinic at KAUH, who were 
clinically assessed and considered as steady state when they were free from pain, 
afebrile, had not been hospitalised and had not suffered a vaso-occlusive episode for 
at least 2 weeks prior to blood sampling. Female subjects were not pregnant. No 
patients were receiving hydroxyurea, anti-lipid therapy or had received a transfusion 
within the previous 8 weeks of the start of the study. 
Control Subjects 
The control population consisted of matched age and gender healthy staff members of 
KAUH and King Fahad Medical Research Center, Jeddah. In addition, healthy normal 
volunteer donors from KAUH blood bank, both Saudis and non-Saudi. All controls 
had their HbAA status confirmed, by sickling test, performed within our hospital 
laboratories. An inherent bias may be those blood donors who are of a super healthy 
class. 
Principle of haemoglobin electrophoresis 
Haemoglobin electrophoresis is used for separating and identifying the haemoglobin 
component in blood. Haemoglobin molecules in an alkaline solution have a net 
negative charge. This causes them to move towards the anode at a rate proportional to 
their negative charge. In addition quantitation of HbS and HbF values were assess to 
detect the severity of the disease. 
Dissolved RBC (Hemolysate) was applied to cellulose acetate, at alkaline pH (8.6); 
electrical current was applied to separate normal and abnormal types of haemoglobin 
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in the blood. The haemoglobin proteins were identified by staining these bands and 
comparing their positions with normal controls (Bain et al., 2011).  
Selection criteria for screening of volunteer control subjects: 
The control group used in the present study consisted primarily of volunteer blood 
donors. A questionnaire form was completed following interviewing each donor 
(Appendix 3). These subjects may not be representative of the general population of 
Saudi Arabia, as they have been selected for their high degree of health and well 
being. For example blood donations are only accepted from individual with a blood 
haemoglobin value of 12.5 gm/dL for women and 13.5 gm/dL for men. In addition 
blood donors are screened for a plethora of disorders, including HIV 1 and 2 
antibodies, Hepatitis B (surface and core antigens and antibodies), Hepatitis C Virus 
RNA, Hepatitis B Virus RNA Syphilis antibodies. Some analyses require fresh blood 
samples, so colleagues and staff members, at KAUH, were a perfect source, their help 
is always appreciated. 
The numbers of subjects in different studies were variable, depending on the flow of 
patients to emergency room and haematology clinic. But the statistical measure of 
power was established latter. This was convenient for establishing the statistical 
power of test. 
Ethical Approval  
Ethical approval was obtained from the Ethics Committee at King Abdulaziz 
University Hospital, Jeddah, Saudi Arabia (Appendix 1). Informed consent was 
obtained from each of the control subjects, from adult patients and also the parent or 
guardian of children, prior to participation in the study. A research questionnaire form 
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was developed (Appendix 2) and forms were completed during interviewing each 
participant. The questionnaire noted the date of birth, nationality, history of infection 
and other clinical and laboratory relevant information.  
Study Population 
Patients and control subjects were residents in the country of Saudi Arabia and were 
assigned to two groups, Saudi and non-Saudi. This was determined in accordance to 
their nationality in their official documents. 
2.2 Study of Infection in Sickle Cell Anaemia Patients  
Selection of Subjects 
In this retrospective study, a review of medical records was carried out for known 
Saudi and non-Saudi homozygous sickle cell anaemia patients with acute vaso-
occlusive crisis admitted to the Haematology Department at King Abdulaziz 
University Hospital, Jeddah, Saudi Arabia, from January 2006 through to December 
2008. During the two years of the study, samples from febrile sickle cell patients in 
acute vaso-occlusive crisis were taken for bacterial culture.  
The study involved 232 patients, all of whom were suffering from SCA in acute VOC. 
Sixty seven patients were deferred, as they were free from any signs of sepsis, or 
otherwise had no fever. Culture and sensitivity tests were negative in 113 patients and 
positive in 52 patients. The patients with documented infection totalled 29 males and 
23 females, ranging in age from 18-46 years with a mean age of 29.6 years. 
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Importantly ethical approval to review the records of those patients was obtained from 
the Ethical Committee at King Abdulaziz University Hospital, Jeddah, Saudi Arabia 
(Appendix 1). 
Sample Collection 
Fifty two patient samples were taken from suspected infection sites for culture and 
sensitivity test by microbiological techniques as follows: 
 Skin swabs from 5 patients with skin infection, sputum culture from 11 patients with 
chest infection, blood culture from 19 patients with high fever, and urine culture from 
17 patients with urinary symptoms. 
Principle of Study 
This study was conducted through the utilization of microbiological tests so as to 
identify the most common organisms in each group through culture and sensitivity 
tests. 
2.3 Analysis of Leukocyte Phagocytic Function  
Sample Collection 
Blood samples were collected from homozygous asymptomatic SCA patients 
presented in a steady state without infection as defined by the fact that they were 
afebrile and had no other concurrent acute or chronic medical illness. From each 
patient 2 ml of blood was collected by venepuncture in to a heparinised tube, and 
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stored at room temperature. Samples were processed within 24 hours for flow 
cytometric analysis. The subjects were 17 female and 14 male patients, ranging in age 
from 14-43 years with a mean age of 22.5. The control population comprised twenty-
five (25) age matched healthy volunteers (13 females, 12 males).  
Principle  
This study utilised flow cytometry to measure the capacity or activity of the 
phagocytic function of neutrophil and monocytes in each group. The technique 
required fresh heparinised whole blood, which was incubated with FITC-labeled E-
coli bacteria at 37 oC and a negative control sample, which remained on ice. The 
phagocytosis was stopped by placing the sample on ice and adding quenching 
solution. Notably, this solution permitted discrimination between the attachment and 
internalisation of bacteria by quenching of FITC fluorescence of surface bound 
bacteria leaving the fluorescence of internalised (phagocytosed) particles unaltered. 
The E-coli bacteria were opsonised with immunoglobulin and complement from 
pooled sera. Monocytes and neutrophils have receptors for a complement component 
(C3b) and for the constant part of the immunoglobulin molecule (Fc), mediating the 
adhesion of the bacteria to the cell surface. Through utilising the methodology of this 
commercially available kit, the capability of the phagocytic cells in SCA was 
determined.  
Procedure  
The phagotest kit was obtained from Becton Dickinson (USA), and used according to 
manufacturers’ instructions. This kit quantified phagocytic activity in granulocytes 
and monocytes in whole blood.  
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Heparinised whole blood was mixed for three seconds on a vortex mixer and 
aliquoted into 100 μl per tube, using 5ml tubes. Care was taken to ensure that no 
blood remained on the sidewall of the tubes. The blood samples were incubated in an 
ice bath for 10 minutes. The pre-cooled bacteria were then mixed well (vortex mixer) 
and 20 μl were added per test to the whole blood. All test tubes were mixed once 
more and subsequently incubated for ten minutes at 37 oC in a water bath, whilst the 
control samples remained on ice. Following incubation, all samples were removed 
from the water bath simultaneously and subsequently placed on ice in order to prevent 
phagocytosis. Ice-cold quenching solution (100 μl) per test was added and the 
samples were mixed on the vortex mixer. A washing solution of 3ml was added to 
each tube and mixed. The tubes were then centrifuged for five minutes at 2100 rpm 
(250xg) at 4 oC. The supernatant was then discarded. The samples were washed with 
3 ml of washing solution once again. The whole blood was lysed and fixed with 2 ml 
of lysing solution, diluted 1 in 10 and prewarmed to 23 oC. Samples were then mixed 
and incubated for 20 minutes at room temperature, and subsequently centrifuged at 
(250xg) for five minutes at 4 oC. The supernatant was discarded and the samples were 
washed once more with 3 ml of washing solution, with centrifugation at (250xg) for 5 
minutes at 4 oC. Podium iodide 200 μl was added to each tube. The tubes were mixed 
and incubated on ice with light protection for 10 minutes. The cell suspension was 
analysed using the flow cytometric analysis scan (FACScan). 
2.4 Flow Cytometric Analysis (FACScan)  
Flow cytometric analysis was achieved through utilising the blue green excitation 
light (488 nm argon-ion laser). During data acquisition, a ‘live’ gate was set in the red 
fluorescence histogram on those events, which had at least the same DNA content as 
human diploid cells (i.e., excluding bacterial aggregates having the same light 
scattering properties as leukocytes). Between 10,000 and 15,000 cells per sample 
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were analysed. The percentages of neutrophil and monocyte cells that had completed 
phagocytosis were analysed. The number of ingested bacteria was indicated through 
utilizing of the mean fluorescence intensity. 
The relevant leukocyte cluster was gated using the software program in the scatter 
diagram (linear Forward Scatter, FSC versus linear Side Scatter, SSC), and the green 
fluorescence histogram was analysed. The control sample was used to set a marker for 
fluorescence histogram so that less than 1% of the events were positive.  
The percentage of phagocytosing cells in the test sample was then determined by 
counting the number of events, above this marker position. The mean fluorescence 
correlated with the number of bacteria per individual leukocytes (Ormerod, 2000; 
Stewart & Nicholson, 2000). 
2.5 Immunophenotyping and Expression of Leukocyte Adhesion 
Molecules  
Selection of Subjects 
The study was carried out on 36 SCA patients in a steady state. There were 22 female 
and 14 male patients, the ages of whom ranged from 10–40 years with a mean age of 
24.40 years. The control population consisted of 34 age matched healthy volunteers 
(17 females, 17 males) from a pool of normal blood donors. 
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Sample Preparation  
Venous blood was obtained by venepuncture into tubes anticoagulated with EDTA 
from patients with SCA at both phases (the acute crisis and the steady state). 
Complete blood counts, including red blood cells (RBCs), leukocytes, platelets, and 
flow cytometry analysis, were performed on all samples. Complete blood counts were 
performed using a Coulter LH750 counter (Coulter, USA). 
The calculation of the total leukocyte count permitted the determination of an absolute 
lymphocyte count, with the use of automated haematology analyser. From these 
values, the lymphocyte subsets were calculated through multiplying the percentages 
(acquired from the flow cytometry) by the absolute lymphocyte count (derived from 
the automated haematology analyser results). 
Principle  
Flow cytometry is a technique applied to make rapid measurements of individual 
particles or cells as they flow in a fluid stream through a sensing point. The method is 
based on the ability of laser and arc lamp-based flow cytometer to measure multiple 
cellular parameters, using light scatter and fluorescence (Salzman et al., 1975). The 
applications of flow cytometry and cell sorting are numerous. Conjugation of 
fluorescent dyes to ligands and to polyclonal and monoclonal antibodies has enabled 
the study of the density and distribution of cell-surface and cytoplasmic determinants 
and receptors, as well as further permitting the identification of functional 
subpopulations of cells (Jackson, 1990). 
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Immunophenotyping Assay Procedures  
Immunophenotyping was performed and analysed using the CellQuest software 
(Becton Dickinson, USA). An aliquot 100 µl of whole blood was added to 20 µl of 
the appropriate fluorochrome-conjugated monoclonal antibody (Becton Dickinson Tri 
test reagents, USA) and vortexed gently. The above mixture was incubated for 15-30 
minutes in the dark at room temperature (20-25 oC), after which 2 ml of FACS lysing 
solution (Becton Dickinson, USA) was added. The mixture was vortexed gently and 
again incubated for 10 minutes in the dark. The sample was centrifuged at (500xg) for 
5 minutes and the supernatant was then removed. Wash buffer (2-3 ml; phosphate 
buffered saline containing 0.1% sodium azide, filtered through 0.2 µm), was added to 
the mixture, and then centrifuged as above. The supernatant was removed and 0.5 ml 
of 1% paraformaldehyde was added and mixed thoroughly. The sample was then 
stored at 2-8 oC until analysed on the FACS Caliber flow cytometer (Becton 
Dickinson, USA). 
Quality control procedures were performed with each batch of samples, according to 
manufacturer’s instructions. IgG1 and IgG2a antibodies were used as negative 
controls.  
The following monoclonal antibodies was obtained from (Becton Dickinson, USA), 
were used in steady state SCA patients.  
1. CD3+ (FITC) / CD4+ (PE) / CD45+ (PerCP)   T helper cells 
2. CD3+ (FITC) / CD8+ (PE) / CD45+ (PerCP)  T suppressor cells 
3. CD19+ (PE) / CD45+ (PerCP)    B cells 
4. CD3+ (FITC) / CD16+56+ (PE) / CD45+ (PerCP) NK cells 
5. CD33+ (FITC) /CD13+ (PE)     Myelocyte  
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6. CD14+ (FITC) / CD64+ (PE)    Monocyte & neutrophil 
7. IgG1 (FITC)/IgG2a (PE)    Negative control 
Additional monoclonal antibodies were used in patients with SCA in acute vaso-
occlusive crisis: 
8. CD 62L (APC) /CD14+ (L selectin / monocytes)  
9. CD 62L (APC)/CD64+ (L selectin / granulocytes)  
10. CD 62L (APC)/ CD19+ (L selectin / lymphocytes)  
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Gating  
The evaluation of different leukocytes is facilitated when they are separated 
graphically from one another. Satisfactory discrimination of leukocytes can be 
accomplished with the utilization of light scatter parameters. Forward Scatter (FSC), 
Side Scatter(SC), wich are functions of cell size and complexity respectively, are used 
to define the various leukocyte types: lymphocytes, monocytes and granulocytes 
(Marti et al., 1986). Moreover, the process of gating is used to analyse a desired cell 
subpopulation out of the total population. During this process, analysis gate is set 
around cell populations in question (Kasschau et al., 1996).  
Multiset leukogate with multiset software were used to establish a lymphocyte 
analysis gate so as to permit automatic analysis of the gated cells. Setting manual 
gating was unnecessary for lymphocytes, although other leukocytes did require 
manual gating. In the manual procedure, arrow keys or the mouse were used to 
position the cursor once leukocyte subpopulations were located on the screen. The 
goal was to obtain a leukogate that included 95% or more of the normal mature 
leukocytes in the sample. The fluorescence display quadrants and the corresponding 
colours were indicated with the gate description shown on the screen. 
Quality Control in Clinical Flow Cytometry  
Successful flow cytometric analysis depends upon the sample preparation, fluorescent 
reagent, instrument calibration, and accurate sample and data analysis. Quality control 
procedures encompassed all of these aspects of flow cytometry, in order to determine 
the precision and accuracy of the procedure and to ensure optimal results (Marti et al., 
1986). The best results are obtained when flow cytometric analyses are performed 
with fresh samples, notably it is important to establish the appropriate conditions after 
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sample collection. A variety of factors can affect leukocyte constancy, including the 
storage temperature (Telen, 2001), anticoagulant and storage time (Nicholson et al., 
1984). Fluorescent reagent quality control includes the evaluation of the saturable 
binding concentrations of the reagents and the determination of specific binding to the 
cell of interest. 
2.6 Determination of Soluble E-selectin and P-selectin 
Sample Collection 
Venous blood samples were collected from patients with SCA at both phases (the 
acute vaso-occlusive crisis and the steady state) and normal healthy control subjects. 
Blood from each subject (2.0 ml) was placed in a plain tube, which was permitted to 
clot at  
 room temperature for 30 minutes. Serum was separated via centrifugation of the 
collected blood for 15 minutes at a speed of (1000xg). All sera were aliquoted and 
stored at -200C until studied as one batch at the end of the study. The median age was 
27 years, ranging from 15-45 years. Females were fifty five% (46) and forty five% 
(38) were males. Further samples were collected from normal healthy control subjects 
with no family history of SCA, forty eight% were female and fifty two% were male. 
The median age was 27 years, ranging from 18-45 years.  
Principle  
Soluble E-selectin and sP-selectin kits were obtained from R&W systems, (USA)  and 
were used to estimate these two proteins, through quantitative sandwich enzyme 
73 
 
immunoassay (Bisset et al., 2004) technique as described previously (Blum et al., 
2005). A monoclonal antibody specific for sE-selectin or sP-selectin was pre-coated 
onto a microplate. Standards, samples and controls were pipetted into the wells and 
the immobilised antibody bound any sE-selectin or sP-selectin present. After washing 
away any unbound substances, an enzyme-linked monoclonal antibody specific for 
sE-selectin or sP-selectin was added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution was added to the wells and 
colour was developed in proportion to the amount of sE-selectin or sP-selectin bound 
in the initial step. The colour development was then stopped and the intensity 
measured. 
Procedure 
All reagents and samples assayed were brought to room temperature for analysis. 
Patients, controls and standards were assayed in duplicate. 
Strips coated with a mouse monoclonal antibody against sE-selectin or sP-selectin 
were prepared. An aliquot (100 µl) of assay diluent RDIW (a buffered protein 
solution) was added to each well. An aliquot (100 µl) of standard patient serum 
control was then added and subsequently covered with the adhesion strip. Samples 
were incubated for 2 hours at room temperature. The content of each well was 
accordingly aspirated and the well was washed. The process was repeated three times 
in total and four washings were performed by filling each well with 400 µl wash 
buffer. Following the last wash, the remainder of the wash buffer was removed 
through decanting. The conjugate of sE-selectin or sP-selectin 200 µl was added to 
each well, covered with a new adhesive strip, and subsequently incubated for 2 hours 
at room temperature. Each well was then aspirated and washed using 400 µl of 
washing buffer. Moreover, a total of four washes were performed, then 200 µl of 
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substrate solution, was added to each well and then incubated for 30 minutes at room 
temperature in a dark room. Stop solution 50 µl (2N sulphuric acid) was added to 
each well. The colour in the wells changed from blue to yellow. The absorbance of 
each well was determined within 30 minutes using a microplate reader (Spectro 
Reader State Fax-2100, Awareness Technology Inc. Palm City, and Fl 34990) 
adjusted to 450 nm. 
Calculation 
The duplicate reading for each standard, control and samples was averaged and 
accordingly the zero standard absorbance was subtracted from the average.  
A standard curve was created by plotting the mean absorbance for each standard on 
the Y-axis against the concentration on the X-axis and a curve was drawn through the 
points on the graph. The data was then linearalised by plotting the log of the sE-
selectin and sP-selectin concentrations versus the absorbance. The concentration of 
selectin was read from the standard curve and multiplied by x10 (dilution factor) for 
sE- selectin and by x15 for sP–selectin. A standard curve was presented (Appendix4). 
2.7 Statistical Analysis  
Computer aided statistical analysis of data from the study was performed using the 
Student unpaired t-test. The t-test was used to establish statistical differences between 
sickle cell anaemia patients in steady state, and sickle cell anaemia patients in vaso-
occlusive crisis compared to normal healthy control subjects. Student unpaired t-test 
was used to compare two independent sample means. Independence indicates that the 
values from both samples are numerically unrelated of each; there was no correlation 
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between corresponding values. The data populations follow the normal distribution. 
Results were then expressed as mean ± standard deviation (SD). Differences between 
groups were analysed with analysis of variance (ANOVA) for multiple comparisons. 
The limit of significant statistic differences was set at p < 0.05. All statistical analysis 
was performed using SPSS (version 15.0; SPSS Inc., Chicago) software package.  
  
 
 
CHAPTER 3  
  
76 
 
CHAPTER 3: PATTERNS OF BACTERIAL INFECTION 
IN SICKLE CELL ANAEMIA 
3.1 Introduction 
Patients with SCA are prone to develop bacterial, viral and parasitic infections. 
Worldwide, infections are a major cause of mortality in SCA, particularly in children. 
Infections remain the leading cause of death, both in the developed and especially in 
the developing world. Infection was implicated in 20-50% of deaths in prospective 
cohort studies over a period of 20 years (Booth et al., 2010). Indirectly the sickle gene 
confers an increased susceptibility to infection, particularly to certain bacterial 
pathogens, and at the same time, infection provokes a cascade of SCA specific 
pathophysiological changes. Infection is one of the major precipitating factors for 
VOC. Furthermore parvovirus infection is the underlying risk factor for aplastic crisis 
(Lowenthal et al., 1996; Serjeant et al., 1993).  
Infection has long been identified as a cause of sickle sequestration crisis particularly 
acute chest syndrome (ACS). Streptococcus pneumoniae was considered to be the 
most common infectious agent implicated in chest infection. Penicillin prophylaxis 
and vaccination programs reduced the pneumococcal infection rate and reports 
showed that Chlamydia pneumoniae and Mycoplasma pneumoniae are now becoming 
the most common infectious agents responsible for ACS (Bernard et al., 2007; 
Vichinsky et al., 2000). Furthermore, chest infection could mimic ACS secondary to 
sequestration crisis which require both treatment modalities; blood transfusion as well 
as antibiotic coverage (Vichinsky et al., 2000). In the developed countries, measures 
to prevent infection including vaccination programmes, use of prophylactic 
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antibiotics, and successful treatment of infection have contributed to improvements in 
survival and quality of life of patients with SCA (Booth et al., 2010; Kizito et al., 
2007).  
Aims and Objectives 
The aim of this study was to investigate the incidence of infection in SCA patients 
with acute vaso-occlusive crisis. The following objectives were pursued:  
• To identify the incidence and site of infections in SCA patients with acute 
vaso-occlusive crisis. 
• To identify the most common causative organisms in these cases of SCA 
patients. 
3.2 Methods 
The microbiological techniques applied in this study are described below. 
Blood specimen collection and culture 
Samples were collected from patients, with suspected sepsis or bacteremina for 
culture and sensitivity. At least two sets of aerobic and anaerobic bottles were 
collected from SCA patients. All blood culture bottles were incubated at 35 oC, in 
blood culture machine (Bact Alert Biomerieux, Bac T ALERT3D system 
(ORGANON TECNIKA) Microbial analysing system 43003-1) and were assessed by 
an automatic detection system (Bact Alert Biomerieux). While negative bottles were 
kept for 5 days, positive blood culture bottles were subjected to Gram and methylene 
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blue stains. In addition, positive samples were sub-cultured onto the plated media, 
including Chocolate, Mac Conkey’s and Blood agar. Finally, based on the Gram stain 
results, Gram-positive cocci, Gram-positive bacilli, Gram-negative cocci, Gram-
negative bacilli and yeast cells were identified.  
Manually directed identification and antibiotic susceptibility testing were performed 
on the bottles containing positive samples, which were also subjected to direct VITEK 
II (Biomerieux) Microbial analysing system VTK2-2972, identification and 
susceptibility tests. 
Sputum specimen collection and culture 
Early morning sputum samples were obtained from the SCA patients, as these contain 
pooled overnight secretions, in which pathogenic bacteria are more likely to be 
concentrated. Sputum samples were processed promptly upon arrival at the 
Microbiology laboratory. 
All sputum samples were Gram-stained to establish the specimen quality. Samples 
characterized by high levels of polymorph nuclear leukocytes and low number of 
epithelial cells were selected for culture. These samples were cultured on Blood, 
Chocolate and Mac Conkey's agar and were incubated for 48 hours at 35 − 37 oC. 
Blood and Chocolate agar cultures were incubated in a CO2 incubator, as this 
environment supports the growth of pathogenic Capnophiles, such as Hemophilus 
influenzae, and Streptococcus pneumonia. On the other hand, MacConkey's agar 
cultures were incubated in an aerophilic incubator, which facilitated the growth of all 
facultative anaerobes, such as Enterobacteria ceae, Pseudomonas, Staphylococcus, 
Streptococcus, and Enterococcus. 
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Midstream urine specimen collection and culture 
Midstream urine samples were collected using the clean-catch technique, whereby a 
sterile wide-mouthed container that can be covered with a tightly fitted lid ensured 
that any potential for sample contamination was eliminated. Based on the established 
values for urine colony counts, which should range between 10,000 and 100,000 
colony forming unit (CFU/ml), it was expected that those pertaining to the infected 
patients would exceed 100,000 CFU/ml. To obtain this data and achieve accurate 
colony counts, all collected specimens were processed within two hours following 
collection. 
Urine specimens were cultured on Biplates (Blood and MacConkey's agar) and 
subsequently incubated for 24 hours at 35 oC. 
Skin lesions swab specimen collection and culture  
As surface lesions are colonized by environmental bacteria, swabs were collected 
from infected skin surfaces after proper cleaning with an antiseptic. This protocol 
helped reduce the bacterial growth of skin contaminants, such as Coagulase negative, 
Staphylococcus. The collected skin swabs were cultured on Blood, Mac Conkey's and 
Sabouraud's dextrose agar, prior to 24-hour incubation at 35 – 37oC. When the 
incubation period elapsed, the cultures were checked for the growth of 
Staphylococcus, Streptococcus, yeast, fungi and facultative anaerobic Gram-negative 
enterobacteriaceae. All skin lesion swabs were subsequently Gram-stained and 
assessed for high PMN'S count under high power field microscopy (Koneman, 2006). 
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3.3 Results  
Table  3.1 displays the incidence of infections in sickle cell anaemia patients with 
vaso-occlusive crisis. There was a total of 232 SCA patients with VOC. Sixty seven 
of these (29%) had no signs of infection, and therefore were excluded (no culture was 
made), of the remaining 165 patients they were febrile. Full septic screen was done, 
113 patients (49%) of total 232 came up with negative culture, and where as 52 
patients (23%) of total 232 had positive bacterial cultures.    
Table  3.2 shows the most common sites of infection and the percentage of positive 
culture samples of SCA patients with VOC. About one third of them (19) patients 
(37%) had a positive blood culture, whilst the second most common site of infection 
was the urinary tract as indicated by one third (17) patients (33%). Positive sputum 
samples were obtained from a further one fifth (11) patients (21%) while 5 patients 
(12%) gave positive cultures from skin and wound swabs. 
Table  3.3 shows the numbers and percentages of isolated microbial organisms from 
patients with SCA in VOC. Staphylococcus aureus was the most frequently isolated 
organisms, it was found in about 29% of patients. Escherichia coli, Staphylococcus 
epidermidis, Pseudomonas aeruginosa had 10% occurrence. Klebsiella pneumonia 
was isolated from 8% of patients, while Enterococcus faecalis, Acinetobacter 
baumannii and Staphylococcus hominis were found in about 6% of patients. Less 
common organisms such as Streptococcus pneumonia, Serratia marcescens and 
Salmonella species which were isolated in 4% of patients. Finally, Streptococcal 
agalactiae, Streptococcus Salivarius and Streptococcus haemolyticus were reported in 
only 2% of patients. 
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Table  3.1 Incidence of infections in sickle cell anaemia patients with vaso-occlusive crisis 
Studied groups  Number Percentage 
SCA patients without culture  67 28.8 
SCA patients with negative culture 113 48.7 
SCA patients with positive culture 52 22.4 
Total SCA patients with  Vaso-occlusive 
crisis 232 100 
 
 
Table  3.2 Sites of infections and percentage of positive culture samples of sickle cell anaemia 
patients with vaso-occlusive crisis  
Sample Number Percentage 
Blood  19 36.54 
Urine  17 32.69 
Sputum  11 21.15 
Pus (skin and subcutaneous infection)  5 9.62 
Total SCA with Vaso-occlusive crisis 52 100.00 
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Table  3.3 Number and percentage of isolated microbial organisms from patients with sickle cell 
anaemia in vaso-occlusive crisis 
Organisms 
isolated Skin Sputum Urine Blood Total Percentage 
Staphylococcus 
aureus 2 5 1 7 15 28.8 
Escherichia coli     3 2 5 9.6 
Pseudomonas 
aeruginosa   1 3 1 5 9.6 
Staphylococcus 
epidermidis   1 2 2 5 9.6 
Klebsiella 
pneumonia   2 1 1 4 7.6 
Enterococcus 
faecalis     3   3 5.7 
Acinetobacter 
baumannii 2   1   3 5.7 
Staphylococcus  
hominis       3 3 5.7 
Streptococcus 
pneumonia   2     2 3.8 
Serratia 
marcescens 1   1   2 3.8 
Salmonella  
species       2 2 3.8 
Streptococcal 
agalactiae     1   1 1.9 
Streptococcus  
salivarius        1 1 1.9 
Streptococcus 
haemolyticus     1   1 1.9 
Total 5 11 17 19 52 100 
Percentage 9.62 21.15 32.69 36.54 100.00   
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3.4 Discussion 
The present study has found that there was a significant increase in the incidence of 
bacterial infection (22.4%) compaired to other studies. The incidence of bacteraemia 
in 52 SCA patients, in acute VOC, was 22.4%. Staphylococcus aureus was the most 
prominent organism comprising 28.8% of infections.  
Similar results were found in a study by Akuse (1996), in Nigeria, who reported the 
presence of bacterial infections in 304 children with SCA in acute VOC. Sixty per 
cent of the patients had positive bacterial cultures, with Gram negative organisms 
accounting for 55 %, but the single most predominant organism isolated was 
Staphylococcus aureus (Akuse, 1996). The low isolation rate of Streptococcus 
pneumoniae, Haemophilus influenzae and Neisseria meningitidis is due to implication 
of vaccination program in SCA and initial antibiotic treatment.  
 In Uganda, East Africa, a study was conducted by Kizito et al., (2007), that included 
a group of 155 SCD patients, 47 of whom had bacteraemia. A positive blood culture 
for Staphylococcus aureus accounted for 60% of these cases, while another common 
organism isolated was Staphylococcus epidermis (9%). These findings are similar to 
the current study. This similarity could be due to high prevelance of these organisms 
in the environment and on the skin. Haemophilus influenzae and Streptococcus 
pneumoniae accounted for 19% and 6% of bacteraemia cases, respectively. 
Streptococcus viridans and Escherichia coli were the least common organisms 
causing bacteraemia.  
In contrast to this study, Streptococcus pneumoniae was the main causative organisms 
of bacteraemia in western countries (Isaacman et al., 2010; Overturf, 2003). 
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In the USA, a study conducted in the period between 1993-2001, on 248 febrile 
children with SCD demonstrated that Streptococcus pneumoniae accounted for 42% 
of bacteraemias, followed by Salmonella species (17%), Staphylococcus aureus (7%) 
and Escherichia coli (5%) (Rogovik et al., 2010).  
The study findings have been inconsistent with the study conducted by Williams et al. 
(2009) in Kenya. The most commonly detected organisms in 2157 bacteraemia cases 
from 38441 SCA patients (6%) were Streptococcus pneumoniae (41%), non-typhi 
Salmonella species (18%), Haemophilus influenzae type b (12%), Acinetobacter 
species (7%) and Escherichia coli (7%) (Williams et al., 2009). This discrepancy may 
be attributed to the age of patients, number, duration of the study and possible 
vaccination against Streptococcus pneumoniae, Haemophilus influenzae and Neisseria 
meningitides.  
Homozygous sickle patients have an increased risk of developing severe pyrogenic 
infections, related to diminish or absent splenic function, by repeated splenic 
infarction, which may lead to a chronic inflammatory state due to insufficient 
clearance of bacteria and subsequent leukocytes activation (Al-Jam'a et al., 2000).  
Staphylococcus aureus was the most commun isolated organism in this study and this 
is in agreement with Valour et.al., who reported that Staphylococcus aureus accounts 
for 2-5% of community aquired pneumonia, and 20-30% of cases of hospital aquired 
pneumonia (Valour et al., 2013). 
Similar study showed that Staphylococcus aureus was the most frequent hospital 
aquired infection from frequent hospitalisation (Schaumburg et al., 2013).  
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This study has demonstrated a high incidence of urinary tract infection 32.7% in a 
mixed population of SCA patients in acute VOC. The data are in agreement with 
other studies that have reported also a high incidence of urinary tract infections in 
SCD (Hawasawi et al., 1998; Kizito et al., 2007). In the present study the most 
common isolated organisms from urine samples were Pseudomonas aeruginosa, 
Escherichia coli and Enterococcus faecalis, while Kizito et al., (2007) found 
Escherichia coli as the common causative organism. 
In another study conducted in Saudi Arabia on 53 SCD patients, the incidence of 
urinary tract infection was 69 %, but the most common organism was Escherichia coli 
(Hawasawi et al., 1998). 
In contrast to the present finding, Hawasawi et al., (1998) demonstrated that 
Streptococcus pneumoniae was the most common organism in SCD patients with 
bacteraemia. Similarly, Rogers et al., (1990) reported that invasive infection by 
encapsulated organisms, such as Streptococcus pneumoniae and Haemophilus 
influenzae was common in young children with SCA, who showed an increased risk 
of pneumococcal bacteraemia and Haemophilus influenzae bacteraemia compared to 
age-matched children without SCA.  
In Saudi Arabian patients with SCA, included in this study, pneumococcal infection 
has low risk of morbidity and this could be contributed to the introduction of vaccines 
(Hawasawi et al., 1998). 
Mortality has significantly decreased in university of Texas southwestern medical 
center, since the introduction of universal vaccination for Streptococcus pneumoniae 
and Haemophilus influenzae in SCA patients (Rogers et al., 1990). 
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Conclusively, this study reflects the magnitude of the problem in Saudi Arabia, 
namely a high incidence of Staphylococcus aureus, (non MRSA) and Pseudomonas 
aeruginosa infection among SCA patients with acute VOC. Generally, since infection 
is conttributing risk factor for VOC in SCA patients, early treatment of infection is 
important for manegment. The introduction of antibiotic prophylaxis, universal 
vaccination and early detection of infection are highly recommended for managing 
patients with SCA. 
  
 
 
CHAPTER 4  
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CHAPTER 4: ANALYSIS OF LEUKOCYTES IN SICKLE 
CELL ANAEMIA 
4.1 Introduction  
Sickle cell anaemia patients undergo various pathophysiological crises that includes 
systemic inflammatory processes. Therefore, it is important to evaluate the role of the 
leukocytes in the different clinical presentations. Under normal conditions, leukocytes 
migrate through all body tissues; the cells exist in the blood are those in transit 
between different tissues. Each cell population has a particular pattern of migration, 
which is dependent on the state of cell differentiation and activities (Roitt et al., 
2002). During infection phagocytic cells, including neutrophils and monocytes leave 
the bone marrow and migrate to sites of infection (Takeshi & Shin, 2003). The 
phagocytic process can be separated into several major stages: chemotaxis, migration 
of phagocytes, attachment of particles to the cell surface of phagocytic cell, ingestion 
and intracellular killing by oxygen dependent and oxygen independent mechanisms 
(Roitt et al., 2002).  
Sickle cell anaemia is considered to be a chronic inflammation state. Numerous 
inflammatory markers are elevated in the steady state and further increased during 
VOC, including C reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), 
leukocytes, platelets, α-2 macroglobulin, transferrin, fibrinogen, and interleukins 1, 4, 
6 and 8 (IL-1 IL-4, IL-6, and IL-8) (Belcher et al., 2000; Hebbel et al., 2004). 
Inflammation appears to play an important role in vaso-occlusion, (Lard et al., 1999). 
Leukocytes have been involved in the production and secretion of injurious 
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substances leading to tissues injury. The neutrophil is described as a ‘messy eater’ due 
to phagocytosis and the killing of microbial organisms, which is followed by the 
release of different cytotoxic proteins. 
These proteins include collagenase, chymotrypsin-like cationic proteins, elastase, 
hydrolase and proteases (Okpala, 2004b). Cytotoxic proteins also attract and recruit 
other leukocytes to inflammatory site. During this process leukocytes releases highly 
reactive oxygen radicals that lead to oxidative damage and cytotoxicity. All these 
processes lead to the expression of ligands for adhesion molecules on leukocytes and 
at the site of inflamed endothelium with further lumen occlusion, ischaemic organ 
damage and eventually VOC. Elevated leukocytes counts in patients with SCA, was 
suggested to be a risk factor for morbidity and mortality (Okpala, 2006).  
Increasing evidence suggests that white blood cells (WBC), especially neutrophils, 
may be involved in the initiation and propagation of VOC in SCA (Kasschau et al., 
1996). Elevated total WBC counts are common in SCA patients and are associated 
with an increased risk of early death (Kasschau et al., 1996). Adhesion of activated 
neutrophils to endothelium in patients with SCA would impede passage of RBC and 
WBC, lead to endothelial damage which would eventually increase risk for VOC 
(Kasschau et al., 1996; Ramakrishnan et al., 2010). Acquired functional asplenia in 
SCA is associated with inefficient phagocytosis of opsonized bacteria. Wong et al., 
(1995) studied the cellular immunity and leukocyte subsets count among patients with 
SCA. They found that there was a broad-based leukocytosis in SCA patients (Wong et 
al., 1995). All T-and B- cell subsets participate in the lymphocytosis in SCA patients. 
Lard et al., (1999) studied the activation state of leukocytes in SCA, and study has 
demonstrated significant increase in L-selectin and neutrophil markers in SCA with 
acute VOC as compared to control subjects. 
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 Immunophenotyping through flow cytometry is a major tool in the study of the 
characteristics of leukocytes as it allows the identification and description of cell 
subsets that cannot be recognized by classical morphologic examination (Givan, 
1992; Marie-Christine & Martini, 1997). With this technique, monoclonal antibodies 
specific to individual epitopes are conjugated with fluorescent labels and are used to 
identify cell surface antigens. The labeled cells can then be detected and enumerated 
by flow cytometry (Schmitz, 2003, 2004). 
The aims of flow cytometry in this study were: 
• To determine leukocyte phagocytic function in neutrophils and monocytes, in 
Saudi and non-Saudi SCA patients in steady state and normal control subjects, 
and compared to Saudi and non-Saudi normal control subjects. 
• To assess gender difference in leukocyte phagocytic function, in both Saudi 
and non-Saudi SCA patients, in steady state and normal control subjects. 
• To compare leukocyte immunophenotyping of Saudi and non-Saudi SCA 
patients in steady state and in normal control subjects.  
• To compare differences in leukocyte immunophenotyping between Saudi and 
non-Saudi SCA patients in acute VOC and normal control subjects.  
• To assess for gender differences in leukocyte immunophenotyping in SCA 
patients; in both steady state and in acute VOC.    
• To compare differences in the expression of L-selectin in leukocytes in Saudi 
and non-Saudi SCA patients in acute VOC, with that of normal control 
subjects. 
• To assess for gender difference in the expression of L-selectin in leukocytes in 
SCA patients in acute VOC.   
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4.2 Methods 
Activated neutrophil and monocyte phagocytic function was performed as previously 
described in Chapter 2, section 2.3. 
Immunophenotyping assay procedure was performed as previously described in 
Chapter 2, sections 2.4 and 2.5. 
4.3 Results 
Leukocyte Phagocytic Function in Sickle Cell Anaemia 
Serum samples from patients with SCA in a steady state and normal control subjects 
were analysed in order to determine whether there were any differences between the 
two groups. Activated neutrophil and monocyte phagocytic activity was performed as 
illustrated in Figure  4.1 and Figure  4.2. 
Statistical analysis using an independent Student t-test was performed in order to 
compare changes in phagocytic activity markers between steady state and normal 
control subjects. Measurements were expressed as mean ± standard deviation (SD), t-
test and p-value, with P<0.05 as an indicator of statistical significance.  
The current study included 14 male SCA patients (25%), 17 female patients (30%), 12 
(21.4%) male and 13 female (23.2%) normal control subjects 
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Figure  4.1 Activated (C) and non activated (B) leukocytes using flow cytometry. (*FL1: 
Fluorescence-1 intensity). This figure shows the increased fluorescence of neutrophil and 
monocyte , upon activation (4.1A)  
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Figure  4.2 Dot plots FSC/SSC and FL1 histograms of the phagocytosis test. This figure shows the 
activated neutrophil (A) and monocytes populations (B) following gating.  
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Phagocytic Activity  
Figure 4.1. and 4.2 are examples of the phagotest results. The mean ± SD of activated 
leukocytes phagotest values, for the two groups, are presented in Table  4.1. The mean 
± SD of neutrophils percentage phagocytosing bacteria (% activated neutrophils) was 
93.53 ± 6.61 % for SCA patients during steady state and 93.54 ± 5.59% for control 
subjects. Notably, there was no significant difference in the activated neutrophil 
percentage in SCA patients, in steady state, compared with normal control subjects. 
The mean ± SD of bacteria per cell (activated neutrophils) was 851.3 ± 36.74 for SCA 
patients during steady state and 840.43 ± 34.61 for normal control subjects. 
Accordingly, no significant differences between the two groups were found. The 
mean ± SD of monocytes phagocytosing bacteria percentage (activated monocytes %) 
were 81.36 ± 10.49% for SCA patients during steady state and 86.87 ± 6.1% for 
control subjects. Noteworthy, there was no significant difference in the percentage of 
activated monocyte phagocytic activity in SCA patients in steady state compared with 
normal control subjects. 
The mean ± SD of bacteria per cell (activated monocytes %) was 754.33 ± 45.83 for 
SCA patients during steady state and 777.63 ± 49.76 for control subjects. This 
difference is statistically insignificant. 
Phagocytic Activity in Male and Female Patients  
The means (± SD) of leukocyte phagocytic activity (neutrophils and monocytes) in 
males and females SCA patients in steady state and in normal control subjects are 
presented in Table  4.2. The mean ± SD for the percentage of activated neutrophils 
was 92.13 ± 7.68% in male SCA patients with steady state, whilst in female with SCA 
patients in steady state was 94.69 ± 5.56%. There was no significant difference found 
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in neutrophils percentage of phagocytic activity between the two groups. Moreover, 
the mean ± SD of activated neutrophils percentage in male control subjects was 95.96 
± 2.92%, and in female control subjects was 91.3 ± 6.59%.  
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Table  4.1 Comparison of percentage of activated leukocytes (phagotest) between sickle cell anaemia patients in steady state and normal control subjects 
Phagotest results 
Sickle cell patients during 
steady state Normal control subjects  
t-test p-value 
Mean ±SD Mean ±SD 
Neutrophils (%) of phagocytes 
which have ingested bacteria 
(activated neutrophils %) 
93.53 6.61 93.54 5.59 0.002 0.99 
In neutrophils number of  bacteria 
per cell 851.3 36.74 840.43 34.61 1.12 0.261 
Monocytes (%) of phagocytes 
which have ingested bacteria 
(activated monocytes %) 
81.36 10.49 86.87 6.1 2.45 0.182 
In monocytes number of bacteria 
per cell 754.33 45.83 777.63 49.76 1.82 0.741 
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There was no significant difference, in terms of percentage, regarding the neutrophil 
phagocytic activity, between the two groups. Moreover, the mean ± SD for activated 
monocytes was 83.07 ± 7.95% in male SCA patients in steady state, whilst in female 
SCA patients with steady state was 79.95 ± 12.27%. Furthermore, no significant 
difference in the percentage of phagocytic activity for monocytes was established 
between the two groups. The mean ± SD for activated monocytes percentage in male 
control subject was 89.86 ± 2.58% and female control subjects was 84.11 ± 7.16%. In 
addition, there was no significant difference, in terms of percentage of monocyte 
phagocytic activity, between the two groups. 
Mean Fluorescence Intensity (MFI) in Male and Female Patients 
Table  4.2 shows the mean ± SD for MFI of neutrophils and monocytes in both male 
and female SCA patients in steady state, and in normal control subjects. The mean ± 
SD for MFI of neutrophils was 848.74 ± 41.92 and 853.41 ± 33.04 in male and female 
SCA patients in steady state respectively. There was no significant difference in terms 
of the MFI of neutrophils phagocytic activity between the two groups. The mean ± 
SD for MFI of neutrophils was 826.75 ± 25.44 in male normal control subjects and 
for female normal control subjects was 853.06 ± 37.98. There was no significant 
difference noted in the MFI of neutrophils phagocytic activity between the two 
groups. The mean ± SD for MFI of monocytes was 752.76 ± 50.37 in male SCA 
patients in steady state, and in female SCA patients in steady state was 755.62 ± 
43.38. Furthermore, there was no significant difference in the MFI of monocytes 
phagocytic activity between the two groups. In male normal control subjects, the 
mean ± SD MFI of monocytes was 760.06 ± 31.47, and for female normal control 
subjects, the mean ± SD was 793.85 ± 58.74. Accordingly, no significant difference in 
the MFI of monocytes phagocytic activity was noted between the two groups. 
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Table  4.2 Comparison of phagocytic activity in male and female sickle cell anaemia patients during steady state and normal control subjects. 
  Cells Gender N 
% activated cells 
t-test P-value 
MFI 
t-test P-value 
Mean ±SD Mean ±SD 
Sickle cell 
patients in steady 
state 
Neutrophils 
M 14 92.13 7.68 
1.08 0.29 
848.74 41.92 
0.35 0.731 
F 17 94.69 5.56 853.41 33.04 
Monocytes 
M 14 83.07 7.95 
0.82 0.42 
752.76 50.27 
0.17 0.872 
F 17 79.95 12.27 755.62 43.38 
Normal control 
Subjects  
Neutrophils 
M 12 95.96 2.92 
2.25 0.06 
826.75 25.44 
2.02 0.065 
F 13 91.3 6.59 853.06 37.98 
Monocytes 
M 12 89.86 2.58 
2.63 0.07 
760.06 31.47 
1.77 0.092 
F 13 84.11 7.16 793.854 58.74 
*MFI: Mean fluorescence intensity 
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Phagocytic Activity in Saudi and Non- Saudi Patients 
A comparative data for mean ±SD of leukocyte phagocytic activity (neutrophils and 
monocytes) in Saudi versus non- Saudi SCA patients in steady state and in normal 
control subjects are presented in Table  4.3. The mean ± SD of activated neutrophils 
(%) was 94.43 ± 6.67% in Saudi SCA patients in steady state and in non-Saudi was 
92.45 ± 6.61%. Notably, there has been no significant difference found in terms of 
percentage of neutrophil phagocytic activity between the two groups. The mean ± SD 
for the percentage of activated neutrophils in Saudi control subjects was 92.4 ± 5.99 
and in non-Saudi was 96.85 ± 1.87. There was no significant difference, regarding the 
percentage of neutrophil phagocytic activity between the two groups. The mean ± SD 
of percentage of activated monocytes was 84.5 ± 6.73 in Saudi SCA patients in steady 
state and 77.51 ± 13.02 in non- Saudi. There was no significant difference in the 
percentage of monocyte phagocytic activity between the two groups. The mean ± SD 
of percentage of activated monocytes in Saudi control subjects was 85.67 ± 6.27 and 
in non-Saudi was 90.68 ± 3.81. Moreover, there was no significant difference in terms 
of the percentage of monocyte phagocytic activity between the two groups. 
Mean Fluorescence Intensity (MFI) in Saudi and Non-Saudi Patients: 
Table  4.3 shows the mean ± SD for MFI of neutrophils and monocytes in Saudi and 
non-Saudi SCA patients in steady state and in normal control subjects. The mean ± 
SD for MFI of neutrophil was 854.35 ± 32.29 in Saudi SCA patients in steady state 
and the mean ± SD in non-Saudi was 847.60 ± 42.47. Moreover, there was no 
significant difference in MFI of neutrophils phagocytic activity between the two 
groups. The mean ± SD for MFI of neutrophils was 836.69 ± 35.68 in Saudi normal 
control subjects, whilst the mean ± SD for non-Saudi was 852.29 ± 30.75. 
Importantly, there was no significant difference in the MFI of neutrophil phagocytic 
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activity between the two groups. The mean ± SD for MFI of monocytes in SCA 
patients in steady state in the case of Saudi and non-Saudi samples was found as 
760.88 ± 39.42 and 746.38 ± 53.03 respectively. There was no significant difference 
in the MFI of monocytes phagocytic activity between the two groups. In Saudi normal 
control subjects the mean ± SD for MFI of monocytes was 776.33 ± 49.93 and for 
non-Saudi was 781.76 ± 53.7. There was no significant difference established in terms 
of the MFI of monocytes phagocytic activity between the two groups. 
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Table  4.3 Comparison of phagocytic activity between Saudi and non-Saudi sickle cell anaemia patients in steady state and in normal control subjects. 
  Cells Ethnic group N 
% activated cells 
t-test P-value 
*MFI 
t-test P-value 
Mean ±SD Mean ±SD 
Sickle cell 
patients in 
steady state 
Neutrophils 
Saudi 17 94.43 6.67 
0.83 0.42 
854.35 32.29 
0.5 0.612 non-
Saudi 14 92.45 6.61 847.6 42.47 
Monocytes 
Saudi 17 84.5 6.73 
1.94 0.06 
760.88 39.42 
0.87 0.391 non-
Saudi 14 77.51 13.02 746.38 53.03 
Normal 
control 
subjects 
Neutrophils 
Saudi 19 92.4 5.99 
1.74 0.09 
836.69 35.68 
0.96 0.353 non-
Saudi 6 96.85 1.87 852.29 30.75 
Monocytes 
Saudi 19 85.67 6.27 
1.84 0.08 
776.33 49.93 
0.23 0.821 non-
Saudi 6 90.68   781.76 53.7 
*MFI: Mean fluorescence intensity 
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Leukocyte Immunophenotyping in Steady State  
Major leukocyte population 
The percentage of total T lymphocytes, T helper cells, T suppressor cells, B 
lymphocytes, NK cells, monocytes and neutrophils in peripheral blood were estimated 
based on the expression of (CD3++CD7+), CD4+, CD8+, CD19+, (CD16+ 56+), CD14+ 
and CD64+ respectively. Statistical analysis observed for the proportions of these cells 
are outlined in Table  4.4. 
The mean ± SD of the percentage of total T lymphocytes (CD3++ CD7+) was 72.0 ± 
9.4 for SCA patients during steady state and 58.5 ± 5.8 for normal control subjects.  
Accordingly, there was a significant higher percentage of (CD3++ CD7+) total T 
lymphocytes in SCA patients in steady state compared with normal control subjects 
(P<0.001). The mean ± SD of the percentage of T helper lymphocyte cells (CD4+) 
was 39.2 ± 8.7 for SCA patients during steady state and 33.5 ± 5.6 for normal control 
subjects. This reflects a significant higher percentage of CD4+ T helper lymphocyte 
cells was found in SCA patients in steady state compared with normal control subject 
(P<0.002). The mean ± SD of the percentage of T suppressor lymphocyte cells CD8+ 
was 29.0 ± 5.8 for SCA patients during steady state and 21.4 ± 5.0 for normal control 
subjects. This represents a significantly higher percentage of CD8+ T suppressor 
lymphocyte cells in SCA patients in steady state, compared with normal control 
subjects (P<0.001). Furthermore, the results for the CD19+ B lymphocytes showed 
that the mean ± SD was 18.6 ± 6.5% for SCA patients during steady state and 12.7 ± 
5.7% for normal control subjects. There was also a higher significant percentage of 
CD19+ B lymphocytes in SCA patients in steady state when compared with normal 
control subjects (P<0.001). The mean ± SD of (CD16+ 56+) NK cells percentage was 
22.4 ± 10.7 for SCA patients during steady state and 18.4 ± 7.5 for normal control 
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subjects. Furthermore, there was a significant difference of (CD16+ 56+) NK cells in 
SCA patients in steady state when compared with normal control subjects (P=0.05).
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Table  4.4 Statistical analysis of percentage of leukocytes in sickle cell anaemia patients in steady 
state compared to the normal control subjects, using Student’s t-test 
Leukocyte Case/control N Mean ±SD t -test P-value 
T lymphocytes 
(CD3++CD7+) 
Steady state 36 72 9.4 
7.21 0.001 
Control 34 58.5 5.8 
T helper cells 
(CD4+) 
Steady state 36 39.2 8.7 
3.32 0.002 
Control 34 33.5 5.6 
T-suppressor 
cells (CD8+)  
Steady state 36 29 5.8 
5.82 0.001 
Control 34 21.4 5 
B lymphocytes 
(CD19+) 
Steady state 36 18.6 6.5 
4.03 0.001 
Control 34 12.7 5.7 
NK cells 
(CD16++56+) 
Steady state 36 22.4 10.7 
1.83 0.05 
Control 34 18.4 7.5 
Monocytes 
(CD14+) 
Steady state 20 2.8 1.7 
0.12 0.898 
Control 20 1.8 1.3 
Neutrophils 
(CD64+) 
Steady state 20 94.1 4.7 
0.93 0.371 
Control 20 95.3 3.7 
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The mean ± SD of CD14+ monocytes percentage was 2.8 ± 1.7 for SCA patients 
during steady state and 2.8 ± 1.3 for normal control subjects. Notably, there was no 
significant difference of CD14+ monocytes in SCA patients in steady state compared 
with normal control subjects. Results for CD64+ neutrophils percentage showed that 
the mean ± SD was 94.1 ± 4.7 for SCA patients during steady state and 95.3± 3.7 for 
normal control subjects. Furthermore, there was no significant difference of CD64+ 
neutrophils in SCA patients in steady state compared with normal control subjects.  
Major Leukocyte Population in Male and Female Patients 
Table  4.5 shows the statistical analysis of leukocyte percentage in male and female 
sickle cell anaemia patients in steady state. The mean ± SD of the percentage of total 
T-lymphocyte cells (CD3++ CD7+) was 60.1 ± 9.6 for male SCA patients during 
steady state and 57.5 ± 9.3 for females. No significant difference was found between 
genders in relation to (CD3++ CD7+) total T lymphocyte. The mean ± SD of the 
percentage of CD4+ T helper lymphocyte cells was 34.1 ± 7.4 for male SCA patients 
during steady state and 33.1 ± 9.6 for females. Markedly, there was no significant 
difference established in regard to gender-related CD4+ T helper lymphocyte cells. 
The mean ± SD of the percentage of CD8+ T suppressor lymphocyte cells was 24.2 ± 
5.8 for male SCA patients during steady state and 19.7 ± 5.2 for females. No 
significant difference was apparent in gender-related CD8+ T suppressor lymphocyte 
cells. The mean ± SD of the percentage of CD19+ B lymphocytes was 19.0 ± 5.5 for 
male SCA patients during steady state and 18.3 ± 7.2 for females. Accordingly, there 
was no significant difference found in gender- related CD19+ B lymphocytes. 
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Table  4.5 Statistical analysis of percentage of leukocytes in male and female sickle cell anaemia 
patients in steady state, using Student’s t-test 
Leukocyte Sex N Mean ±SD t -test P-value 
T lymphocytes 
(CD3++CD7+) 
Male 14 60.1 9.6 
0.81 0.422 
Female 22 57.5 9.3 
T helper cells (CD4+) 
Male 14 34.1 7.4 
0.33 0.742 
Female 22 33.1 9.6 
T suppressor cells 
(CD8+) 
Male 14 24.2 5.8 
2.42 0.062 
Female 22 19.7 5.2 
B lymphocytes (CD19+) 
Male 14 19 5.5 
0.34 0.757 
female 22 18.3 7.2 
NK cell (CD16+56+) 
Male 14 22.2 9.9 
0.12 0.943 
female 22 22.5 11.3 
Monocytes (CD14+) 
Male 7 2.8 2.3 
0.13 0.971 
Female 13 2.8 1.5 
Neutrophil (CD64+) 
Male 7 94.2 3.9 
0.04 0.972 
Female 13 94.1 5.2 
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The mean ± SD of the percentage of (CD16+ 56+) NK cells was 22.4 ± 9.9 for male 
SCA patients during steady state and 22.5 ± 11.3 for females. There was no 
significant difference found in gender-related (CD16+ 56+) NK cells. The mean ± SD 
of the percentage of CD14+ monocytes was 2.8 ± 2.3 for male SCA patients during 
steady state and 2.8 ± 1.5 for females. In addition, there was no significant difference 
apparent in gender-related CD14+ monocytes. The mean ± SD of the percentage of 
CD64+ neutrophils was 94.2 ± 3.9 for males SCA patients during steady state and 
94.1 ± 5.2 for females. Furthermore, there was no significant difference apparent in 
terms of gender- related CD64+ neutrophils.  
Major Leukocyte Population in Saudi and Non- Saudi Patients  
Table  4.6 shows the percentage of leukocytes in Saudi and non-Saudi sickle cell 
anaemia patients in steady state. The mean ± SD of the percentage of total T 
lymphocyte (CD3++ CD7+ ) was found as 57.6 ± 8.4 and 59.5 ± 10.5 for Saudi and 
non-Saudi SCA patients respectively during the steady state. Moreover, there was no 
significant difference in (CD3++ CD7+) total T lymphocyte in Saudi SCA patients in 
steady state compared with non-Saudi. The mean ± SD of the percentage of CD4+ T 
helper lymphocyte was 32.5 ± 8.4 for Saudi SCA patients during steady state and 34.6 
± 9.2 for non-Saudi. Moreover, there was no significant difference in CD4+ T helper 
lymphocyte cells in Saudi SCA patients in steady state compared with non-Saudi. The 
mean ± SD of the percentage of CD8+ T suppressor lymphocyte was 22.0 ± 6.1 for 
Saudi SCA patients during steady state and 20.8 ± 5.6 for non-Saudi. Accordingly, 
there was no significant difference in CD8+ T suppressor lymphocyte in Saudi and 
non-Saudi SCA patients in the steady state. 
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Table  4.6 Statistical analysis of percentage of leukocytes in Saudi and non-Saudi sickle cell 
anaemia patients in steady state, using Student’s t-test 
Leukocyte Nationality N Mean ±SD t -test P-value 
T lymphocytes 
(CD3++CD7+)  
Saudi 19 57.6 8.4 
0.616 0.541 
Non-Saudi 17 59.5 10.5 
T helper cells 
(CD4+) 
Saudi 19 32.5 8.4 
0.712 0.482 
Non-Saudi 17 34.6 9.2 
T suppressor cells 
(CD8+) 
Saudi 19 22 6.1 
0.623 0.542 
Non Saudi 17 20.8 5.6 
B lymphocytes 
(CD19+) 
Saudi 19 18.7 6.7 
0.088 0.93 
Non-Saudi 17 18.5 6.6 
NK lymphocytes 
(CD16+56+) 
Saudi 19 22.5 12 
0.101 0.92 
Non-Saudi 17 22.2 9.2 
Monocytes (CD14+) 
Saudi 10 2.9 1.8 
0.054 0.951 
Non-Saudi 10 2.8 1.8 
Neutrophil (CD64+) 
Saudi 10 92.8 6.1 
1.288 0.212 
Non-Saudi 10 95.4 2.1 
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The mean ± SD of the percentage of CD19+ B lymphocytes was 18.7 ± 6.7 for Saudi 
SCA patients during steady state and 18.5 ± 6.6 for non-Saudi. In addition, there was 
no significant difference in the percentage of CD19+ B lymphocytes in Saudi SCA 
patients in steady state compared with non-Saudi. The mean ± SD of the percentage 
of (CD16+56+) NK cells was 22.5 ± 12.0 for Saudi SCA patients during steady state 
and 22.2 ± 9.2 for non-Saudi. Notably, there was no significant difference in (CD16+ 
56+) NK cells between Saudi and non-Saudi SCA patients in steady state. The mean ± 
SD of the percentage of CD14+ monocytes was 2.9 ± 1.8 for Saudi SCA patients 
during steady state and 2.8 ± 1.8 for non-Saudi. Furthermore, there was no significant 
difference in CD14+ monocytes in Saudi SCA patients in steady state compared with 
non-Saudi. The means ± SD of the percentage of neutrophils CD64+ was 92.8 ± 6.1 
for Saudi SCA patients during steady state and 95.4 ± 2.1 for non-Saudi. Moreover, 
no significant difference in the percentage CD64+ neutrophils in Saudi SCA patients 
in steady state was established when compared with non-Saudi.  
The estimation of absolute numbers of T helper lymphocyte and T suppressor 
lymphocyte in peripheral blood was based on expression of CD4+ and CD8+ 
respectively. The absolute numbers for these cells in the study population are outlined 
in Table  4.7. The mean ± SD of the absolute number of CD4+ T helper lymphocyte 
cells was 2.6 x109/L ± 1.7 for SCA patients during steady state and 2.0 x109/L ±1.1 
for normal control subjects. Essentially, there was no significant difference 
established in absolute CD4+ T helper lymphocyte in SCA patients in steady state 
compared with normal control subjects. The mean ± SD of the absolute number of 
CD8+ T suppressor lymphocyte was 1.7 x109/L ± 1.0 for SCA patients during steady 
state and 1.5 x109/L ±1.0 for normal control subjects. There was no significant 
difference in the CD8+ absolute T suppressor lymphocyte in SCA patients in steady 
state compared with normal control subjects. 
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The ratio of CD4+ T helper lymphocytes to CD8+ T suppressor cells was 1.5 x109/L ± 
0.6 for SCA patients during steady state and 1.3 x109/L ± 0.4 for normal control 
subjects (Table  4.8). Remarkably, there was a significant difference in CD4+:CD8+ 
ratio, in SCA patients when compared with normal control subjects (P<0.05).      
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Table  4.7 Statistical analysis of T lymphocytes in sickle cell anaemia patients in steady state 
compared to the normal control subjects, using Student’s t-test  
Leukocyte Sample type N Mean (x109/L) ±SD t -test P-value 
T helper cells 
CD4+ (absolute)  
Steady state 36 2.6 1.7 
1.956 0.552 
Control 34 2 1.1 
T suppressor 
CD8+ (absolute)  
Steady state 36 1.7 1 
0.636 0.527 
Control 34 1.5 1 
 
 
Table  4.8 Ratio of T lymphocyte cells CD4 + helper to CD8 + T suppressor in sickle cell anaemia 
patients in steady state compared to the normal control subjects, using Student’s t-test  
  Sample type N Ratio ±SD t -test P-value 
CD4+/CD8+ cell 
ratio 
Steady state 36 1.5 0.6 
2.205 0.03 
Control 34 1.3 0.4 
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Leukocyte Immunophenotyping in Acute Vaso-Occlusive Crisis  
Major Leukocyte Population   
The percentage of the total T lymphocytes, T helper, T suppressor, B lymphocytes, 
NK cells, monocytes and neutrophils in peripheral blood were estimated, based on 
expression of CD3++ CD7+, CD4+ and CD8+, CD19+, (CD16+56+), CD14+, CD64+ 
and CD62+ L (lymphocytes, neutrophils, monocytes) respectively, Lymphocytes 
(CD62+L/CD19+) , neutrophils (CD62+L/CD64+) and monocytes (CD62+L/CD14+). 
The percentage values for these phenotypic cells in study population are outlined in 
Table  4.9.    
The mean ± SD of the percentage of T lymphocytes (CD3++ CD7+) was 69.84 ± 8.73 
for SCA patients in acute VOC and 69.48 ± 10.11 for normal control subjects. There 
was no significant difference in CD3++ CD7+ T lymphocytes of SCA patients in acute 
VOC, when compared with normal control subjects. The mean ± SD of the percentage 
of CD4+ T helper lymphocytes was 44.04 ± 8.77 for SCA patients in acute VOC and 
44.50 ± 10.05 for normal control subjects. There was no significant difference of 
CD4+ T lymphocyte helper cells of SCA patients in acute VOC, as compared to 
normal control subjects. The mean ± SD of the percentage of CD8+ T suppressor 
lymphocyte cells was 23.69 ± 7.59 for SCA patients in acute VOC and 24.10 ± 7.24 
for normal control subjects. Moreover, there was no significant difference of CD8+ T 
suppressor lymphocytes of SCA patients in acute VOC when compared with normal 
control subjects. The mean ± SD of the percentage of B lymphocytes CD19+ was 
16.01 ± 7.45 for SCA patients in acute VOC and 11.71 ± 5.14 for normal control 
subjects. There was significant difference in the percentage of CD19+ B lymphocyte 
cells in SCA patients in acute VOC when compared with normal control subjects 
(P=0.002). The mean ± SD of the percentage of CD16+56+ NK cells was 14.62 ± 7.19 
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for SCA patients in acute VOC and 11.68 ± 6.34 for normal control subjects. There 
was a significant difference in NK cells (CD16+56+) in SCA patients in acute VOC 
when compared with normal control subjects (P<0.05). The mean ± SD of the 
percentage of CD14+ monocytes was 91.03 ± 5.78 for SCA patients in acute VOC and 
89.02 ± 6.65 for normal control subjects. Furthermore, there was no significant 
difference of CD14+ monocytes in SCA patients in acute VOC when compared with 
normal control subjects. The mean ± SD of the percentage of neutrophils CD64+ was 
94.27 ± 6.84 for SCA patients in acute VOC and 93.68 ± 4.69 for normal control 
subjects. There was no significant difference in CD64+ neutrophils in SCA patients in 
acute VOC when compared with normal control subjects. The mean ± SD of the 
percentage of monocytes (CD62+L/CD14+) was 66.73 ± 13.54 for SCA patients in 
acute VOC and 51.81 ± 17.91 for normal control subjects. Remarkably, there was a 
significant difference in the percentage of monocytes (CD62+L/CD14+) in SCA 
patients in acute VOC when compared with normal control subjects (P=0.01). The 
mean ± SD of the percentage of neutrophils (CD62+L/CD64+) was 93.54 ± 7.50 for 
SCA patients in acute VOC and 89.96 ± 5.31 for normal control subjects. Importantly, 
there was a significant difference in the percentage of neutrophils (CD62+L/CD64+) 
for SCA patients in acute VOC when compared with normal control subjects 
(P<0.05). The mean ± SD of the percentage of lymphocytes (CD62+L/CD19+) was 
55.49 ± 11.23 for SCA patients in acute VOC and 45.14 ± 12.59 for normal control 
subjects. There was a significant difference in the percentage of lymphocytes 
(CD62+L/CD19+) of SCA patients in acute VOC, when compared with normal control 
subjects (P=0.01). 
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Table  4.9 Statistical analysis of percentage of leukocytes in sickle cell anaemia patients in acute 
vaso-occlusive crisis compared to the normal control subjects, using Student’s t-test 
Leukocyte Samples N Mean ±SD t -test P-value 
T lymphocytes 
(CD3++CD7+)  
VOC 52 69.84 8.73 
0.182 0.856 
Control 43 69.48 10.11 
T helper cells (CD4+)  
VOC 52 44.04 8.77 
0.233 0.814 
Control 43 44.5 10.05 
T suppressor cells 
(CD8+)  
VOC 52 23.69 7.59 
0.273 0.786 
Control 43 24.1 7.24 
B lymphocytes 
(CD19+)  
VOC 52 16.01 7.45 
3.207 0.002 
Control 43 11.71 5.14 
NK cells (CD16+56+)  
VOC 52 14.62 7.19 
2.091 0.039 
Control 43 11.68 6.34 
Neutrophils (CD64+) 
VOC 52 94.27 6.84 
0.483 0.63 
Control 43 93.68 4.69 
Monocytes (CD14+)  
VOC 52 91.03 5.78 
1.556 0.118 
Control 43 89.02 6.65 
CD62 L monocytes 
(CD62+L/CD14+)  
VOC 47 66.73 13.54 
4.208 0.011 
Control 37 51.81 17.91 
CD62 L Neutrophils 
(CD62+L/CD64+)  
VOC 47 93.54 7.5 
3.397 0.034 
Control 37 89.96 5.31 
CD62 L lymphocytes 
(CD62+L/CD19+)  
VOC 47 55.49 11.23 
3.917 0.011 
Control 37 45.14 12.59 
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Major Leukocyte Populations in Male and Female Patients       
Table  4.10 shows the leukocytes percentage in male and female sickle cell anaemia 
patients in acute VOC compared to the normal control subjects. The mean ± SD of the 
percentage of the T lymphocytes (CD3++ CD7+) was 67.99 ± 9.76 for male SCA 
patients in acute VOC, and 71.08 ± 7.86 for females. There was no significant 
difference established in gender-related (CD3++ CD7+) T lymphocytes. The mean ± 
SD of the percentage of CD4+ T helper lymphocyte cells was 41.46 ± 8.21 for male 
SCA patients in acute VOC and 45.78 ± 8.82 for females. Moreover, there was no 
significant difference determined in gender-related CD4+ T helper lymphocytes. The 
mean ± SD of the percentage of CD8+ T suppressor lymphocyte cells was 24.2 ± 8.54 
for male SCA patients in acute VOC and 23.28 ± 6.99 for females. Furthermore, there 
was no apparent significant difference in gender- related CD8+ T suppressor 
lymphocytes. The mean ± SD of the percentage of CD19+ B lymphocytes was 17.15 ± 
9.58 for male SCA patients in acute VOC and 15.22 ± 5.60 for females. There was no 
notable disparity established in gender-related CD19+ B lymphocytes. The mean ± SD 
of the percentage of (CD16+56+) NK cells was 15.01 ± 6.85 for male SCA patients in 
acute VOC and 14.36 ± 7.50 for females. There was no significant difference found in 
gender-related (CD16+56+) NK cells. The mean ± SD of the percentage of CD14+ 
monocytes was 92.95 ± 4.42 for males SCA patients in acute VOC and 89.72 ± 6.27 
for females. Moreover, there was no apparent significant difference in gender-related 
CD14+ monocytes. The mean ± SD for the percentage of neutrophils CD64+ was 
95.40 ± 3.68 for male SCA patients in acute VOC and 93.50 ± 8.30 for females. There 
was no apparent significant difference in gender-related CD64+ neutrophils. The mean 
± SD of the percentage of monocytes (CD62+L/CD14+) was 62.26 ± 12.52 for male 
SCA patients in acute VOC and 69.49 ± 13.60 for females. 
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Table  4.10 Statistical analysis of percentage of leukocytes in male and female sickle cell anaemia 
patients in acute vaso -occlusive crisis, using Student’s t-test  
Leukocyte Sex N Mean ±SD t -test P-value 
 T lymphocytes 
(CD3++CD7+)  
Male 21 67.99 9.76 
1.252 0.21 
Female 31 71.08 7.86 
T helper cells (CD4+)  
Male 21 41.46 8.21 
1.783 0.081 
Female 31 45.78 8.82 
T-suppressor cells 
(CD8+) 
Male 21 24.28 8.54 
0.462 0.65 
Female 31 23.28 6.99 
B lymphocytes (CD19+)  
Male 21 17.15 9.58 
0.91 0.363 
Female 31 15.22 5.6 
NK cells (CD16+56+)  
Male 21 15.01 6.85 
0.313 0.752 
Female 31 14.36 7.5 
Monocytes (CD14+)  
Male 21 92.95 4.42 
1.035 0.064 
Female 31 89.72 6.27 
Neutrophils (CD64+)  
Male 21 95.4 3.68 
1.123 0.261 
Female 31 93.5 8.3 
CD62L monocytes 
(CD62+L/CD14+) 
Male 18 62.26 12.52 
1.822 0.072 
Female 29 69.49 13.6 
CD62L Neutrophils 
(CD62+L/CD64+)  
Male 18 93.53 5.31 
1.107 0.063 
Female 29 89.36 8.27 
CD62L lymphocytes 
(CD62+L/CD19+)  
Male 18 53.02 11.77 
1.183 0.245 
Female 29 57.01 10.8 
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No significant difference was found in gender-related (CD62+L/CD14+) monocytes. 
The results of neutrophils in terms of percentage (CD62+L/CD64+) mean ± SD was 
93.53 ± 5.31 for male SCA patients in acute VOC and 89.36 ± 8.27 for females. There 
was no significant difference found in gender-related (CD62+L/CD64+) neutrophils. 
The mean ± SD of the percentage of lymphocytes (CD62+L/CD19+) was 53.02 ± 
11.77 for male SCA patients in acute VOC and 57.01 ± 10.80 for females. There was 
no significant difference found in gender-related (CD62+L/CD19+) lymphocytes. 
Major Leukocyte Population in Saudi and Non- Saudi Patients  
Table  4.11 shows the leukocytes percentage in Saudi and non-Saudi sickle cell 
anaemia patients with VOC. The mean ± SD of the percentage of T lymphocytes 
(CD3++ CD7+) was 69.81 ± 8.75 for Saudi SCA patients in acute VOC and 69.88 ± 
8.91 for non-Saudi patients. There was no significant difference in (CD3++ CD7+) T 
lymphocyte cells in Saudi SCA patients in acute VOC when compared with non-
Saudi patients. The mean ± SD of the percentage of CD4+ T helper lymphocyte cells 
was 45.08 ± 9.65 for Saudi SCA patients in acute VOC and 42.37 ± 7.03 for non-
Saudi patients. There was no significant difference in CD4+ T helper lymphocyte cells 
in Saudi SCA patients in acute VOC when compared with non-Saudi. The mean ± SD 
of the percentage of CD8+ T suppressor lymphocyte cells was 23.88 ± 7.34 for Saudi 
SCA patients in acute VOC and 23.37 ± 8.15 for non-Saudi. There was no significant 
difference in CD8+ T suppressor lymphocyte cells in Saudi SCA patients in acute 
VOC when compared with non-Saudi. The mean ± SD of the percentage of B 
lymphocytes CD19+ was 15.20 ± 6.96 for Saudi SCA patients acute VOC and 17.28 ± 
8.18 for non-Saudi. Moreover, there was no significant difference in CD19+ B 
lymphocyte cells in Saudi SCA patients in acute VOC when compared with non-
Saudi. The mean ± SD of the percentage of (CD16++ 56+) NK cells was 14.86 ± 6.63 
for Saudi SCA patients acute VOC and 14.24 ± 8.16 for non-Saudi. There was no 
significant difference in (CD16 + 56+) NK cells in Saudi SCA patients in acute VOC 
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when compared with non-Saudi. The mean ± SD of the percentage of CD14+ 
monocytes was 91.44 ± 5.92 for Saudi SCA patients acute VOC and 90.37 ± 5.62 for 
non-Saudi. There was no significant difference in CD14+ monocytes in Saudi SCA 
patients in acute VOC when compared with non-Saudi. The mean ± SD of the 
percentage of neutrophils CD64+ was 93.95 ± 7.89 for Saudi SCA patients acute VOC 
and 94.78 ± 4.82 for non-Saudi. There was no significant difference in CD64+ 
neutrophils in Saudi SCA patients in acute VOC as compared to non-Saudi. The mean 
± SD of the percentage of monocytes (CD62+L/CD14+) was 68.49 ± 12.87 for Saudi 
SCA patients in acute VOC and 63.31 ± 14.54 for non-Saudi. There was no 
significant difference in the percentage of monocytes (CD62+L/CD14+) of Saudi SCA 
patients in acute VOC when compared with non-Saudi. The mean ± SD of the 
percentage of neutrophils (CD62+L/CD64+) was 91.29 ± 7.97% for Saudi SCA 
patients in acute VOC and 90.30 ± 6.68 for non-Saudi. Furthermore, there was no 
significant difference in the percentage of neutrophils (CD62+L/CD64+) of Saudi SCA 
patients in acute VOC when compared with non-Saudi. The mean ± SD of the 
percentage of lymphocytes (CD62+L/CD19+) was 57.06 ± 11.83 for Saudi SCA 
patients in acute VOC and 52.42 ± 9.55 for non-Saudi. There was no significant 
difference in the percentage of lymphocytes (CD62+L/CD19+) of Saudi SCA patients 
in acute VOC when compared to non-Saudi.  
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Table  4.11 Statistical analysis of percentage of leukocytes in Saudi and non-Saudi sickle cell 
anaemia patients in acute vaso-occlusive crisis, using Student’s t-test 
Leukocyte Nationality N Mean ±SD t -test P-value 
T lymphocytes 
(CD3++CD7+)  
Saudi 32 69.81 8.75 
0.03 0.97 
Non-Saudi 20 69.88 8.91 
T helper cells (CD4+)  
Saudi 32 45.08 9.65 
1.08 0.28 
Non-Saudi 20 42.37 7.03 
T suppressor cells 
(CD8+)  
Saudi 32 23.88 7.34 
0.232 0.81 
Non Saudi 20 23.37 8.15 
B lymphocytes (CD19+)  
Saudi 32 15.2 6.96 
0.971 0.33 
Non-Saudi 20 17.28 8.18 
NK lymphocytes (CD 
16+56+)  
Saudi 32 14.86 6.63 
0.293 0.76 
Non-Saudi 20 14.24 8.16 
Monocytes (CD14+)  
Saudi 32 91.44 5.92 
0.642 0.61 
Non-Saudi 20 90.37 5.62 
Neutrophils (CD64+)  
Saudi 32 93.95 7.89 
0.423 0.67 
Non-Saudi 20 94.78 4.82 
CD62L monocytes 
(CD62+L/CD14+)  
Saudi 31 68.49 12.87 
1.251 0.21 
Non-Saudi 16 63.31 14.54 
CD62L Neutrophils 
(CD62+L/CD64+)  
Saudi 31 91.29 7.97 
0.426 0.67 
Non-Saudi 16 90.3 6.68 
CD62L lymphocytes 
(CD62+L/CD19+)  
Saudi 31 57.06 11.83 
1.354 0.18 
Non-Saudi 16 52.42 9.55 
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4.4 Discussion   
Leukocyte Phagocytic Function  
The aim of this study was to compare the phagocytic function of neutrophils and 
monocytes, in Saudi and non- Saudi SCA patients.  
Okpala, (2004b) studied neutrophil function in 74 steady state adult patients with 
SCA compared with 50 normal haemoglobin (HbAA) healthy control subjects. The 
results showed significantly reduced neutrophil ability to phagocytose Candida 
albicans. However the study was carried out in moderate and severe cases of SCA. 
Okpala further noted that phagocytic competence correlates positively (P < 0.001) to 
the clinical severity of the disease. The findings of his study were based on Candida 
albicans infection, which was not tested in the current study and may explain the 
discrepancy between the findings.  
The results in Table  4.2 showed no significant statistical differences in the percentage 
of activated neutrophils and monocytes between male and female SCA patients in 
steady state. Similarly, no significant statistical difference was found in normal 
control subject. 
The current study demonstrated that there was no significant difference in MFI of 
neutrophils and monocytes in male and female SCA patients in steady state compared 
to normal control subjects.  
The measurements of the phagocytic function of neutrophils and monocytes were 
analysed further in order to clarify whether population differences can be seen 
120 
 
(Table  4.3). The study has demonstrated no significant difference in the percentage of 
activated neutrophils, monocytes and MFI of phagocytic function between Saudi and 
non–Saudi SCA patients in steady state. In normal control subjects, there was no 
significant difference between Saudi and non-Saudi subjects, no similar studies have 
been reported previously from Saudi Arabia. 
Lard et al., (1999) analysed the activation state of neutrophils by measuring 
neutrophil CD64+. The study included a group of 42 steady state SCD patients, 15 
SCD patients in VOC and 30 healthy volunteers. In this study, a significant difference 
was reported in the activation state of CD64+ neutrophil and CD14+ monocytes, in 
steady state non- symptomatic SCA patients compared to normal control subjects. 
Furthermore, neutrophil activation was more pronounced during VOC. One possible 
explanation for these results may be that they used a flow cytometric analysis to 
measure the activation state of neutrophils by targeting or determining the level of 
expression of neutrophils’ antigens such as CD64+ and CD 14+, rather than measuring 
phagocytic function directly, as in the study presented here.  
In vivo studies suggest that adherent leukocytes bind RBC and contribute to the micro 
vascular pathology that characterises SCA. Increasing evidences indicate that 
activated neutrophils could play an important role in the initiation and propagation of 
vaso-occlusive processes in SCA (Lard et al., 1999). 
Leukocyte Immunophenotyping in Steady State 
The percentage of total (CD3++ CD7+) T lymphocytes, CD4+ T helper lymphocytes, 
CD8+ T suppressor lymphocytes, and CD19+ B lymphocytes and (CD16+56+) NK 
cells were significantly increased in steady state SCA patients as shown in Table  4.4  
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The broad based increase in total (CD3++ CD7+) T lymphocyte, CD4+ T helper 
lymphocyte cells and CD8+ T suppressor lymphocyte cells reflects lymphocyte 
activation caused either by infections and tissue damage or increased bone marrow 
production.  
The finding of a significant increase in the percentage of CD19+ B lymphocyte cells 
reflects immune stimulation secondary to tissue damage. The results reported in this 
study confirmed previous findings by Wong et al., (1995); this study was conducted 
on 173 SCA patients and 131 normal control subjects. Wong et al., (1995) found that 
the percentage of T and B lymphocytes was significantly higher in SCA patients. 
Monocytes CD14+ and CD (16+ + 56+) NK cells were increased as percentages in 
SCA patients as compared with control subjects. Wong et al. reported that the 
increase in NK (CD16+ 56+) cells could be due to antibody-dependent cellular 
cytotoxicity mechanisms that provide important and effective responses to viral 
infections.  
The results in Table  4.4 display the percentage of CD14+ monocytes and CD64+ 
neutrophil in SCA patients in steady state and normal control. There was no 
significant difference in CD14+ monocytes and CD64+ neutrophil in SCA patients in 
steady state as compared to normal control subjects. On the contrary, Wong et al., 
(1995) reported an increase in CD14+ monocytes percentage of SCA patients. 
However, they suggested that this could be due to haemolysis or tissue damage.  
The present study compared absolute CD4+ T helper lymphocyte cells in SCA 
patients in steady state and normal control subjects (Table  4.7), showed no significant 
difference in the CD4+ T helper lymphocyte cells in SCA patients in steady state as 
compared to normal control subjects. Also there was no significant difference in the 
CD8+ absolute T suppressor lymphocyte cells in SCA patients in steady state as 
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compared to normal control subjects. The (CD4+:CD8+) ratio showed significant 
difference. Wong et al., (1995) reported that during sickle cell crisis the (CD4+:CD8+) 
ratio was variably affected. 
Previous study by Donadi & Falcão in 1987 found that the numbers of (CD3++CD7+) 
total lymphocytes, CD4+ T helper lymphocyte cells, CD8+ T suppressor lymphocyte 
cells and CD20+ B lymphocytes were elevated in SCA patients (Donadi & Falcão, 
1987).  
Groom et al., (1991) reported an increased number of lymphocytes (CD2+ T 
lymphocytes, CD4+ T helper lymphocytes, CD8+ T suppressor lymphocytes, CD20+ B 
lymphocytes and CD16+ 56+NK) in acute VOC patients compared to normal control 
subjects (Groom et al., 1991). The CD8+ T suppressors increased by 3-4 folds, CD4+ 
T helpers increased by 2 folds, NK CD16+56+ increased 4-5 folds as well as CD20+ B 
lymphocytes. However CD8+ T suppressors only doubled at the time of acute VOC. 
Therefore, CD4+ T helper and CD8+ T suppressor ratio (CD4+:CD8+) was normal in 
SCA patients in steady state, compared to normal control subjects. The number of 
CD20+ B lymphocytes exceeds that seen in patients with medical and trauma 
emergencies (Groom et al., 1991).  
In the present study there was no significant difference in the percentage of (CD3+ + 
CD7+) total T lymphocyte, CD4+ T helper lymphocytes, CD8+ T suppressor 
lymphocytes and CD19+ B lymphocytes, (CD16+56+) NK cells CD14+ monocytes 
and CD64+ neutrophils in peripheral blood between male and female SCA patients in 
steady state.  
With regards to nationality the percentage of total T lymphocyte (CD3++ CD7+), T 
helper lymphocyte cells CD4+, T suppressor lymphocytes CD8+, and CD19+ B 
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lymphocytes, (CD16+56+ ) NK cells, CD14+ monocytes and CD64+ neutrophils in 
peripheral blood, there was no significant difference between Saudi and non–Saudi 
steady state SCA patients and normal control subjects. 
These results confirm the work of Bisset et al., (2004) who established reference 
ranges for lymphocyte phenotypes in healthy Swiss adults. Neutrophil counts vary 
among different ethnic groups (Martineau et al., 2007).  
Al-Qouzi et al., (2002) and Koffi et al., (2003) demonstrated that the (CD4+:CD8+) 
ratio in SCA patients was 1.5:1.0, compared to 1.3:1.0 in normal control subjects. 
Both Saudi and non Saudi individuals were recruited to the study and no significant 
difference was found between the studied groups (Koffi et al., 2003). This confirms 
earlier findings in the immunophenotyping of lymphocytes in Saudi men (Al-Qouzi et 
al., 2002). 
Leukocyte Immunophenotyping in Acute Vaso-Occlusive Crisis  
The results obtained in this study showed that the percentage of CD19+B 
lymphocytes, CD16++56+ NK cells were significantly increased in SCA patients with 
acute VOC. The percentage of other cells such as total (CD3++CD7+) T lymphocytes, 
CD4+ T helper lymphocytes, CD8+ T suppressor lymphocytes, CD14+ monocytes and 
CD64+ neutrophils were not significantly increased in SCA patients with acute VOC.  
The finding of a significant increase in the percentage of CD19+ B lymphocyte cells 
reflects immune stimulation secondary to tissue damage. 
L-selectin expression of (CD62+L/CD14+) monocytes, (CD62+L/CD64+) neutrophils 
and (CD62+L/CD19+) lymphocytes were significantly elevated in SCA patients in 
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acute VOC as compared to normal control subjects. This confirmed a positive role for 
L-selectin expression in the pathogenesis of VOC. 
These results are in agreement with Okpala et al., 2002, who reported that high 
expression of L-selectin on leukocytes in steady-state, which predisposes patients to 
severe manifestations, and contributed to the pathogenesis of crisis. In addition 
Inwald et al., (2000) reported that vaso-occlusive events in childhood SCA are related 
to inflammatory cell activation, and to interactions between sickle erythrocytes and 
vascular endothelium (Inwald et al., 2000). 
Prior to this study, different observation was reported by Lard et al., (1999) who 
analysed (CD62+L/CD64+) neutrophil L- selectin in SCD patients in VOC. The study 
showed significant reduction in (CD62+L/CD64+) neutrophil L-selectin expression in 
SCD patients in VOC compared to normal control subject. The explanation was 
thought to be due to the shedding of L-selectin during neutrophil activation. 
Therefore, the surface L- selectin expression was low.  
In order to explore the L-selectin expression on the other leukocytes, CD62+L in 
conjunctions with other markers was analysed, e.g (CD62+L/CD19+) for B 
lymphocytes and (CD62+L/CD14+) for monocytes. Another study by Okpala, (2006) 
revealed similar findings, when he showed that L-selectin expression on monocytes, 
neutrophils and lymphocytes was elevated in SCD patient during VOC. 
In addition, Okpala, (2006) found that L-selectin expression was more elevated in 
complicated SCD patients. These findings suggest that high levels of L-selectin and 
other adhesion molecule markers predispose SCD patients to severe manifestations 
and complications. These leukocyte selectin adhesive interactions contribute to blood 
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vessel occlusion in SCD, which is the major mechanism of organ damage (Chiang & 
Frenette, 2005; Okpala, 2006).  
The current study demonstrated that there was no significant statistical difference for 
the percentage of various leukocyte subtypes and L-selectin expression between male 
and female SCA patients in acute VOC. The results for leukocyte markers were 
analysed further, to identify any population difference, between Saudi and non Saudi 
SCA patients during VOC. No significant difference was found in the expression of 
different leukocyte markers or L-selectin in the studied groups. This indicates that 
neither the ethnicity nor the gender had any effect on peripheral blood leukocyte 
phenotype in patients with SCA. 
In conclusion, the phagocytic activity was intact in SCA patients, with no nationality 
or gender differences, when compared with normal control subjects. To the best of the 
current knowledge, there are no previous publications regarding nationality related 
differences therefore the findings of this study are novel. 
Flow cytometric analysis of peripheral blood leukocyte subpopulations from patients 
with SCA in steady state, denotes that there was an elevation in the percentage of T 
helper lymphocytes, T suppressor lymphocytes, B lymphocytes and NK cells 
During VOC, B lymphocytes and NK cells are increased, L-selectin expression on 
neutrophils, monocytes and lymphocytes correlates with their activation. This is due 
to immune stimulation, infections and tissue damage. Therefore, correlation with 
serum L-selectin can be utilised in the future as a marker of activation during acute 
VOC. This finding in the Saudi population has not been reported in prior studies. 
  
 
 
CHAPTER 5  
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CHAPTER 5: Soluble E and P selectin in sickle Cell 
Anaemia in Steady State and Vaso-Occlusive Crisis 
5.1 Introduction 
The endothelial cell participates in numerous functions of vascular physiology. Cell 
adhesion molecules play a major role in the recruitment and binding of inflammatory 
cells to the vascular endothelium. Endothelial cell adhesion molecules including E-
selectin and P-selectin induce specific inflammatory cells to roll across the endothelial 
surface. Strong adhesive interactions develop on endothelial VCAM-1 and ICAM-1 to 
specific ligands on the surface of inflammatory cells (Alon & Feigelson, 2002). The 
expression of these CAM is under the influence of inflammatory cytokines, such as 
TNF-α and IL-1β (Duits et al., 1996).  
In animal models, adhesion molecules were found to mediate vaso-occlusion in 
mouse models of SCA (Belcher et al., 2000; Matsui et al., 2001). A number of studies 
indicate that interactions between sickle reticulocytes, leukocytes, and endothelial 
cells via these adhesion molecules occur in patients with SCA, and may contribute to 
disease pathology (Hebbel et al., 2004; Turhan et al., 2002). 
Adhesion molecule-dependent reticulocyte, monocyte and endothelial interactions in 
the postcapillary venules were suggested to contribute to the pathophysiology of VOC 
(Frenette, 2004). Cytokines by up-regulating CAM, modulate the role of the 
endothelium in coagulation, inflammation and vaso-regulation (Brown et al., 2001). 
High levels of inflammatory cytokines were found in the plasma of patients with SCA 
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(Duits et al., 2003; Makis et al., 2000). High levels of adhesion molecules such as 
soluble endothelium-derived E and P selectin have been found in the sera of patients 
with SCA (Matsui et al., 2002). Such findings might have significant impact on 
targeted therapy aimed at prevention of VOC. Furthermore, sE-selectin and sP-
selectin levels in patients with SCA were associated with pulmonary hypertension, 
organ dysfunction, and mortality (Kato et al., 2005). 
Aims:   
• To investigate the levels of the adhesion molecules sE-selectin and sP-selectin 
in the serum of SCA patients in both steady state and acute VOC, and 
compared with those in the normal control subjects. 
• To determine the difference in the level of the adhesion molecules, sE-selectin 
and sP-selectin between Saudi and non-Saudi SCA patients in both steady 
state and in acute VOC; and compared to normal control subjects.  
 
5.2 Methods 
Soluble E-selectin and sP-selectin were measured through quantitative sandwich 
enzyme immunoassay (Bisset et al., 2004), as described in chapter 2, section 2.6 
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5.3 Results 
The sickle cell anaemia patients with acute VOC aged 18-45 years old took part in 
this study. The age of SCA in steady state ranged between 15 and 45 years. The age 
of normal control subjects ranged between 18 and 45 years.  
Serum samples from SCA patients with acute VOC, steady state and control subjects 
were analysed in order to determine whether there were any disparities in regard to 
the levels of sE-selectin and sP-selectin in these groups.  
Table  5.1 shows the mean ± SD for serum level of sE-selectin for the three groups. 
The mean ± SD of serum level of sE-selectin was 106.90 ± 23.51 ng/ml for SCA 
patients in acute VOC, 66.63 ± 14.57 ng/ml for SCA patient in steady state and 57.25 
± 21.67 ng/mL for normal control subjects.  
ANOVA analysis of variance showed significant (P = 0.001) differences in means of 
sE-selectin between SCA patients with acute VOC, steady state and control subjects.  
Post hoc demonstrated that SCA patients with acute VOC showed significantly (P = 
0.001) higher sE-selectin levels than steady state and control subjects. Moreover, 
steady state patients showed significantly (P < 0.01) higher sE-selectin levels 
compared to control subjects. 
Table  5.2 shows the mean ± SD for serum level of sP-selectin for the three groups. 
The mean ± SD of serum level of sP-selectin was 212.0 ± 73.32 ng/mL for SCA 
patients with VOC, 153.81 ± 28.60 ng/mL for SCA patient in steady state and 127.73 
± 22.75 ng/mL for control subjects.  
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ANOVA analysis of variance showed significant (P = 0.001) differences in means of 
sP-selectin, between SCA patients in acute VOC, steady state and control subjects.  
Post hoc demonstrated that SCA patients with acute VOC showed significantly higher 
(P < 0.001) sP-selectin levels than steady state and control subjects. Moreover, steady 
state patients showed significantly higher (P < 0.01) sP-selectin levels compared to 
control subjects. 
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Table  5.1 Statistical analysis (ANOVA) of soluble E-selectin in normal control subjects compared 
to sickle cell anaemia patients in steady state and acute vaso–occlusive crisis  
  Number Mean (ng/ml) ±SD P- value 
Control 84 57.25 21.67  
Steady state 43 66.63 14.67 0.01 
Vaso-occlusive crisis 41 106.9 23.51 0.001 
 
 
Table  5.2 Statistical analysis (ANOVA) of soluble P-selectin in normal control subjects compared 
to sickle cell anaemia patients in steady state and acute vaso–occlusive crisis  
  Number Mean (ng/ml) ±SD P- value 
Control 84 127.73 22.75  
Steady state 43 153.81 28.6 0.01 
Vaso-occlusive crisis 41 212 73.32 0.001 
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Soluble Adhesion Molecule Markers in Saudi Non-Saudi Subjects 
Table  5.3 shows the mean ± SD of the serum levels of sE-selectin for Saudi and non- 
Saudi control subjects. The mean ± SD of serum levels of sE-selectin was 59.57 ± 
22.45 ng/ml for Saudi control subjects and 54.7 ± 20.77 ng/ml for non-Saudi control 
subjects. No significant difference between the two groups was found, using the 
independent t-test.  
Table  5.4 shows the mean ± SD of sP-selectin for Saudi and non- Saudi control 
subjects. The mean ± SD of serum levels of sP-selectin was 123.36 ± 20.64 ng/ml for 
Saudi control subjects and 132.55 ± 24.23 ng/ml for non-Saudi control subjects. 
Importantly, no significant difference was established in the serum levels of sP-
selectin between Saudi control subjects and non-Saudi control subjects using the 
independent t-test.  
Soluble E-selectin serum levels mean ± SD for Saudi and non-Saudi SCA patients in 
steady state are presented in Table  5.5. The mean ± SD of sE-selectin serum levels 
was 65.34 ± 14.42 ng/ml for Saudi and 67.86 ± 15.14 ng/ml for non-Saudi subjects. 
There was no significant difference in serum levels of sE-selectin between the two 
study groups.  
Table  5.6 shows the mean ± SD of sP-selectin serum levels in steady state for the two 
groups. The mean ± SD of serum levels of sP-selectin was 112.95 ± 27.74 ng/ml for 
Saudi SCA patients and 114.64 ± 30.02 ng/ml for non-Saudi. There was no significant 
difference in the serum levels of sP-selectin in SCA patients in steady state when 
compared with non-Saudi patients. 
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Table  5.3 Statistical analysis of soluble E-selectin in Saudi and non-Saudi normal control subjects 
Nationality Number Mean (ng/ml) ±SD t-test P-value  
Saudi control 44 59.57 22.45 
1.028 0.307 
Non- Saudi  control 40 54.7 20.77 
 
 
Table  5.4 Statistical analysis of soluble P-selectin in Saudi and non-Saudi normal control 
Nationality Number Mean (ng/ml) ±SD t-test P-value  
Saudi control 44 123.36 20.64 
1.88 0.064 
Non- Saudi  control 40 132.55 24.23 
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Table  5.5 Statistical analysis of soluble E-selectin in Saudi and non-Saudi patients with sickle cell 
anaemia in steady state 
Nationality Number Mean (ng/ml) ±SD t-test P-value 
Saudi steady state 21 65.34 14.42 
0.56 0.58 
Non-Saudi steady state 22 67.86 15.14 
 
 
Table  5.6 Statistical analysis of soluble P-selectin in Saudi and non-Saudi patients with sickle cell 
anaemia in steady state 
Nationality Number Mean (ng/ml) ±SD t-test P-value 
Saudi steady state 21 112.95 27.74 
0.91 0.853 
Non-Saudi steady state 22 114.64 30.02 
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Soluble E-selectin level mean ± SD in acute VOC is presented in Table  5.7. The mean 
± SD of sE-selectin serum level was 106.2 ± 25.13 ng/ml for Saudi SCA patients in 
acute VOC and 108 ± 21.51 ng/ml for non-Saudi SCA patients in acute VOC. No 
significant difference was found in the serum levels of sE-selectin in SCA patients in 
acute VOC when compared with non-Saudi SCA patients in acute VOC.   
Table  5.8 shows the mean ± SD sP-selectin serum level in SCA patients with acute 
VOC for the two groups. The mean ± SD of serum level of sP-selectin was 211.2 ± 
67.03 ng/ml for Saudi and 213.25 ± 84.53 ng/ml for non-Saudi. There was no 
significant difference in the serum levels of sP-selectin in Saudi SCA patients in acute 
VOC when compared with non-Saudi SCA patients in acute VOC. 
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Table  5.7 Statistical analysis of soluble E-selectin in patients with sickle cell anaemia in acute 
vaso-occlusive crisis in Saudi and non-Saudi patients 
Nationality Number Mean (ng/ml) ±SD t-test P-value 
Saudi Patients with Vaso-
occlusive crisis 25 106.2 25.13 
0.24 0.81 
Non-Saudi Patients with 
Vaso-occlusive crisis 16 108 21.51 
 
 
Table  5.8 Statistical analysis of soluble P-selectin in sickle cell anaemia patients in acute vaso-
occlusive crisis in Saudi and non-Saudi patients 
Nationality Number Mean (ng/ml) ±SD t-test P-value 
Saudi Patients Vaso-
occlusive crisis 25 211.2 67.03 
0.09 0.93 
Non-Saudi Patients with 
Vaso-occlusive crisis 16 213.25 84.53 
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5.4 Discussion  
This study compared differences in the serum levels of sE-selectin and sP-selectin in 
three subject groups namely SCA patients in acute VOC, patients in steady state and 
normal control subjects (Table  5.1 and Table  5.2). The three groups were age 
matched. Patients with SCA in acute VOC and steady state showed significantly 
higher serum levels of sE-selectin and sP-selectin than normal control subjects (P < 
0.001). Sickle cell anaemia patients in acute VOC had significantly higher (P < 0.001) 
serum level of sE-selectin and sP-selectin compared to SCA patients in steady state. 
These finding were in agreement with previous studies (Blum et al., 2005; Kato et al., 
2005).  
Similar observations were reported by Blum et al., (2005) in regards to endothelial 
adhesion and dysfunction in acute VOC among SCA patients compared to healthy 
volunteers. The results showed a significant difference in the level of sE-selectin 
among patients with SCA in both crisis and steady state as compared with control 
subjects (P < 0.001). The level of sE-selectin was approximately doubled among 
patients with sickle cell crisis as compared to healthy volunteers control subjects. In 
addition, there was a trend towards increased levels of sE-selectin among SCA 
patients in acute crisis versus those in steady state. This finding confirms that the 
heightened levels of sE-selectin confer increased risk of endothelial dysfunction, 
inflammation and endothelial cell activation. These abnormalities characterize not 
only the sickle cell crisis but also the steady state pathophysiology of sickle cell 
anaemia. 
Prior to this study, an extensive work was performed in 2002 by Turhan et al., on E-
selectin and P-selectin as major adhesion molecules that regulate binding to sites of 
inflammation, and their role in SCA patients in acute crisis. Some studies, using sickle 
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transgenic mouse model, have revealed increased adhesive interaction between 
circulating erythrocytes and leukocytes to endothelium, via E-selectin and P-selectin 
and promote VOC. P-selectin is reported to be expressed on endothelial cell surface 
within minutes of endothelial stimulation. On the other hand E-selectin is synthesized 
de novo and requires several hours to be expressed following endothelial stimulation. 
A role for P-selectin in mediating leukocytes and erythrocyte interactions and 
adhesion to endothelium in mice with SCA has been demonstrated by Turhan et al., 
(2002) using both blocking monoclonal antibodies and P-selectin knockout mice. 
Sickle mice deficient in E-selectin and P- selectin were found to be protected from 
vaso-occlusion. This confirms that P-selectin could be considered as a candidate 
molecule for new therapeutic approaches, for the vaso- occlusive manifestations of 
SCA (Matsui et al., 2001), by blocking of the P-selectin molecule. 
A previous study by Mathews et al., (2002), reported that P-selectin was measured in 
SCD patients and compared to normal controls subjects. P-selectin immunoreactivity 
was associated with intraretinal vessels, adjacent to the preretinal neovascular 
formation, in subjects with proliferative retinopathy (Mathews et al., 2002), these data 
suggest that the highest P-selectin immunoreactivity was associated with the vaso-
occlusive phase of SCD, in patients with proliferative retinopathy and might play an 
important part in the vaso-occlusive phase of sickle cell retinopathy. 
Saleh et al., (1998), studied the effect of hydroxyurea on vascular endothelium, 
adhesion molecule expression and cytokine production of sE-selectin and P-selectin 
in, the steady state SCA patients (Saleh et al., 1998). Remarkably, hydroxyurea 
therapy was associated with significant reduction in levels of sE-selectin and sP-
selectin compared to normal control subjects.  
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The result of this study have shown that serum levels of sE-selectin and sP-selectin 
were significantly increased in patients with SCA in acute VOC and steady state. 
However, they were most significant in SCA patients in acute VOC. The data from 
other studies, showed a similar results to this study, in relation to level of sE-selectin 
and sP-selectin (Blum et al., 2005; Kutlar & Embury, 2014).  
Kato et al., (2005) included a group of 160 adult SCA patients in steady state. Serum 
level of sE-selectin and sP-selectin were significantly higher in patients with SCD in 
steady state compared to normal control subjects (P < 0.001 and P < 0.001) 
respectively. Their study demonstrated that elevated levels of serum sE-selectin and 
sP-selectin were a marker of inflammatory stress and disease severity.  
A study conducted by Mohan et al., (2005) included a group of 64 patients with SCD. 
The study revealed that serum level of sE-selectin was significantly higher (P < 
0.001) in SCD patients compared to HbAA normal control subject (P < 0.001) 
(Mohan et al., 2005). This study indicated that raised plasma sE-selectin in SCD was 
an inflammatory marker and implied endothelial activation. 
Brown et al., (2001) found that the exposure of endothelial cells to sickle cells 
demonstrated increased expression of E-selectin. This finding reflects the significant 
role of expressed E-selectin in the pathophysiology of sickle- related complication. 
The reduction in E-selectin expression may be of value in the treatment of SCA. The 
results of this study have confirmed that sE-selectin and sP-selectin are markers of 
endothelial surface activation and indicator of disease severity. 
Furthermore, there was no significant difference in serum levels of sE-selectin and sP-
selectin among the Saudi and non Saudi SCA patients, either in steady state or acute 
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VOC, or when comparing the results of SCA patients with normal control subjects 
(Blum et al., 2005). 
In conclusion, sE-selectin and sP-selectin are valuable markers, in the management of 
SCA. They are indicators for endothelial surface activation and correlate with disease 
severity. This study is novel to Saudi patients and, to the best of the current 
knowledge, no similar work has previously conducted in the Middle East.
  
 
 
CHAPTER 6  
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CHAPTER 6: General Discussion, Future Work and 
Conclusion 
6.1 General Discussion 
Sickle cell anaemia has a prevalence of 0.26% in Saudi Arabia, while up to 4.2 % 
may have sickle cell trait gene (Al-Hamdan et al., 2007). Sickle cell anaemia is a 
systemic disorder caused by a mutation that replaces adenine with thymidine, in the 
sixth codon of the beta-globin gene. This mutation leads to the production of sickle 
haemoglobin (HbS) which is predisposed to polymerisation, upon deoxygenation of 
haemoglobin. Sickle haemoglobin polymerisation and denaturation causes oxidant 
damage to the red blood cell membrane, and subsequently, the unique morphological 
abnormality of sickled red blood cells. Associated with such damage is abnormal 
erythrocyte cation homeostasis, which in turn results in dehydrated, dense, and finally 
irreversibly sickled cells. Red cell abnormalities can result in both haemolysis and 
vaso-occlusion. Vaso-occlusion is a complex event mediated by interaction between 
red cell, leukocyte and endothelial cells, and activation of inflammation and 
coagulation pathways. Haemolysis and the release of cell-free hemoglobin contribute 
to dysregulation of nitric oxide pathway.  
Vaso-occlusion of blood vessels results in tissue ischaemia, infarction in various 
tissues and susceptibility to infections, leading to progressive end organ damage. The 
clinical manifestations of the sickle cell anaemia are the product of various genes and 
enviromental factors, acting in concert with the protein lesion underlying the red cell 
abnormality. Leukocytes adherence to the vascular endothelium, stimulates the latter 
to increase its expression of ligands for adhesion molecules; causing an inflammatory 
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response and tissue damage which in turn leads to vaso-occlusion (Johnson & Telen, 
2008; Okpala, 2004b). The clinical implication of the role of leukocytes in the 
pathophysiology of VOC was highlighted by the fact that high leukocyte count is 
associated with more severe clinical course. (Okpala, 2004b)  
This study is the first of its kind, in the Western region of the Kingdom of Saudi 
Arabia, that addresses health related issues for SCA patients. More specifically, it 
aimed to uncover some of the physiological/immunological patterns in the immune 
system and the relationship between infection and SCA.  
Infection is an important risk factor in the pathogenesis of VOC in patients with SCA, 
therefore early and intensive treatment of infection is required to treat acute crisis 
(Booth et al., 2010). Patients with SCA have an increased risk of developing severe 
bacterial infections, partly due to impaired cellular and humoral immunity (Magnus et 
al., 1999; Steinberg, 1999), and the characteristic functional asplenia. Recurrent 
splenic sequestration, known as autoinfarction, is caused by splenic sequestration of 
red blood cells. The nonfunctional spleen is unable to filter bacteria from the blood 
stream. This leads to a chronic inflammatory state, due to insufficient clearance of 
bacteria and subsequent leukocytes activation (Al-Jam'a et al., 2000; Lard et al., 
1999; Okpala, 2004b; Rogers et al., 1990). Functional asplenia increases the risk of 
invasive infection by encapsulated organism, such as Streptococcus pneumoniae and 
Haemophilus influenzae. Other factors contributing to increased incidence of 
infections, include nutritional deficiency particularly zinc, as well as genetic and 
environmental interactions (Hasanato, 2006; Prasad, 2002; Prasad et al., 1999; 
Tamouza et al., 2002).  
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Prior to universal vaccination children with HbSS had an increased risk of both 
pneumococcal and Haemophilus influenzae sepsis, compared to age-matched children 
without SCA (Rogers et al., 1990).  
As one of the objectives of this study, was to determine the incidence of infection in 
SCA, and to identify the most common causative organisms in these patients. The 
most common organism isolated from blood was Staphylococcus aureus, which is not 
in concordance with other studies (Ramakrishnan et al., 2010). The other common 
infections found in the current study are shown in (Table 3.3). Both pneumococcal 
and Haemophilus influenzae sepsis was not high due to previous vaccination. Another 
important objective met in this study, was to assess the leukocyte function in SCA 
patients in steady state and compared to normal control subjects. Leukocyte function 
was measured by the Phagotest, a well established test which uses flow cytometry to 
assess the uptake of fluorescent bacteria. Phagotest is originally used in the diagnosis 
of combined immune deficiency states and chronic granulomatous disease (Hirt et al., 
1994). 
Overall, the phagocytic function was well preserved with no differences between 
patients, in steady state and normal control subjects. This is in agrrement with 
findings of Lard et al., (1999). 
Flow cytometry analyses in the present study, demonstrated significantly higher levels 
of total T lymphocytes, both helper and suppressor, B lymphocytes and NK cells in 
patients with SCA during steady state, as compared to normal control subjects, and 
this elevation represent the reactivity of the immune system in response to chronic 
inflammatory state in SCA patients. No significant difference was found between 
Saudi and non-Saudi, or between male and female patients. These finding are 
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consistent with those of Wong et al., (1995). Thus, current findings suggest that there 
is no impairment in the defense mechanism for these patients. 
Results show clearly that there was no significant difference in the percentages of 
neutrophils and monocytes that display phagocytic activity in SCA patients in steady 
state as compared to normal control subjects. It is important to consider the possibility 
that intact phagocytic function may contribute to steady state. Supporting these results 
is the data for the immunophenotyping that shows no significant difference of 
monocytes or neurtophils between steady state and normal control subjects. 
Previous studies have argued for a deficiency in the immune response for SCA 
patients as indicated by the reduction of T lymphocytes (Adedeji, 1985; Kaaba & al-
Harbi, 1993). In contrast, this study shows indications of not only intact 
immuophenotyping of lymphocytes and NK- cells but rather a significant increase in 
cytokine receptors for these cells in steady state SCA patients compared to normal 
control subjects. 
Given that the patients in this study are SCA steady state survivors, it is possible that 
T lymphocytes and NK cells overactivation is providing a protective mechanism. This 
protective mechanism could be complemented by the increase of liberation of the 
adhesion molecules of sE and sP selectin.  
One of most important and novel findings of the present study, was the presence of 
high levels of L-selectin on neutrophils, monocytes and lymphocytes during acute 
VOC. Accordingly, as markers for leukocytes activation, L selectin can be used as a 
predictor for VOC, which allows for early diagnosis and intervention (Bunting et al., 
2002; Okpala, 2006). 
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The use of ELISA technology revealed significant differences in sE-selctin and sP-
selectin expression, between patients with VOC and those in steady state of the 
disease. This is in agreement with the findings from Blum et al., (2005). Thus, sP-
selectin and sE-selectin can be used as markers of disease severity. Furthermore, 
therapeutic modalities targeting these inflammatory mediators maybe therapeutic 
options for sickle cell disease. Thus, further studies are needed to examine the 
potential new therapeutic approaches for clinical complications of SCA including 
VOC. These therapeutic approaches could be directed to reverse the activation of 
endothelial cell and/or to develop and use antagonists for selectin ligand. 
The phagocytic activity in patients with SCA is not impaired, compared to matched 
controls and cannot be implicated in the high incidence of infection. Susceptibility to 
infection is compounded by failure to implement a national vaccination protocol for 
SCA patients. Environmental and, genetic factors may contribute to this problem.  
Overall, the results indicate a high level of infection in VOC patients compared to 
other studies, supporting the consensus that VOC predisposes individuals to infective 
agents (Hawasawi et al., 1998; Kizito et al., 2007; Schlitt & Keitel, 1960). However it 
is worth noting that almost two thirds of VOC patients were infection free, suggesting 
that infections are more likely to be associated with VOC but not the cause or an 
ultimate outcome. This could be supported by the finding that the most frequent 
organism (S. aureus) is mostly present in the blood and not necessarily in ischeamic 
parts. Therefore, treatment for VOC is important to be given alongside infection-
targeted treatment, and may even contribute to the preventions of further infections. 
Analysis of SCA patients with VOC indicates a hyper responsive immune system, as 
reflected by the significant rise in the cytokine receptors on T lymphocytes and NK 
cells.  In addition, VOC are associated by an elevation in sE and sP selectin adhesion 
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molecules. Also in comparison with steady state patients, the expression for L-selectin 
increases significantly during VOC. In addition, the data show an increased 
expression in L-selectin on neutrophils, monocytes and lymphocytes in VOC patients.   
When testing associated impact of socio-demographic characteristics of SCA patients, 
including gender and ethnicity, on the state of the immune system, no significant 
difference was seen in our data. This result may be due to non bias of genetic factors. 
Further personalised analysis may be required to investigate detailed differences, 
especially for VOC patients that are subjected to continuous infections. The 
coinheritance of α-thalassaemia and sickle cell genes, in the Eastern province, 
interferes with the sickling process and therefore preserves the splenic function, which 
may explain the lower rates of infection.   
Due to the various ethnic origins among Saudis, a number of SCD haplotypes are 
seen. The severe Benin haplotype is the most common, while the Arab – Indian type 
is less common. This variation provided a unique opportunity, in this study, to 
compare the differences between these haplotypes. 
The clinical implications of these results could be utilized to improve treatment 
outcomes. Implementation of national management protocol for SCA is highly 
recommended. Moreover, vaccination program should be enforced and patient 
identification card issued. All these strategies would help further reductions in the 
incidence of infection, being a major trigger for VOC. 
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6.2 Limitations 
The study has some limitations including the difficulty to recruit matched healthy 
controls. Thus we recruited random, healthy, volunteer blood donors as normal 
control subjects. Volunteer blood donors were readily available and willing to 
participate. Moreover, the demographics of the donor population were similar to the 
study patients.  
Only fresh blood was used for flowcytometry testing and all samples were analysed 
within 24 hours of collection. Thus, samples could not be tested in batches alongside 
the ELISA testing. The more accurate flowcymetry beads methodology was not 
available at the time of the study. Alternatively, the manual technique was used. 
Although the flow of patients coming to the haematology clinic or emergency room 
varied, which affected the number of samples used in the study, the statistical measure 
of power has established post hoc using G power program and was found to be in the 
range of 80-85 %. A larger number of patients would lend more power to the 
statistical analysis.  
Furthermore, follow up of sickle cell patients in clinical studies is difficult, as their 
visits to the out-patient clinics are usually irregular due to repeated hospitalization and 
lack of socioeconomic support. Finally, the scarcity of literature on the association of 
clinical complications of sickle cell disease and leukocyte adhesion markers among 
Saudi patients, made it difficult to compare our results to others.  
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6.3 Recommendations 
In the way to improve the clinical outcome, and the quality of life, for patients with 
sickle cell anaemia, this work highlights the importance of using adhesion molecules, 
on cell membranes, in the diagnosis and treatment. Early disease detection through 
neonatal screening program should be implemented. Premarital screening program for 
the detection of sickle cell anaemia and other haemoglobinopathies should be in 
effect. Attention should be focused on educating patients about the potential benefit of 
antibiotic prophylaxis, along with the role of pneumococcal and Haemophilus 
influenzae vaccination in minimizing the risk of infections. In addition more research 
is needed to explore cell adhesion molecules, a targeted approach to counteract the 
disease manifestations. 
6.4 Scope for Further Studies  
A “pan anti-adhesive” agent is a novel potential therapeutic target, to inhibit selectin-
mediated cell interactions between sickled red blood cells, leukocytes and endothelial 
cells, which is implicated in the pathophysiology of vaso-occlusion. Selectin 
inhibition reduces leukocyte rolling and adhesion, which in turn may increase and 
restore microvascular blood flow. Therefore, it holds promise as a novel therapeutic 
approach for the treatment of vaso-occlusion. Moreover, it has the potential to reduce 
disease related morbidity and end-organ damage. Further clinical research of this 
therapeutic approach may help improve quality of life for sickle cell disease patients 
and reduce the burden of disease management on the healthcare system throughout 
Saudi Arabia. 
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6.5 Conclusion 
The overall findings of the current study support data from other reports on patients 
with SCA in different parts of the world. The present results confirm that cell 
adhesion molecules play a major role in the pathophysiology of SCA, as reflected by 
the novel finding of increased levels of L-selectin on the surface of leukocytes, as 
well as the increased levels of sE-selectin and sP-selectin in serum. High levels of 
these markers suggest that these could be used to monitor VOC and could be targeted 
for novel therapeutic approach. However, a multi-center study is recommended to 
further elucidate the nature of interaction between haplotype and cell adhesion 
molecules in the pathogenesis of VOC. The findings of this study may also be 
significant to the quality of life of SCA patients.  
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 Name :________________________________________   Age:_______   Nationality:____________________  
 Hafeeza/iqama number:_____________ Address____________________ Occupation :_____________________  
 Tel-home:___________    tel-work:______________  mobile:_____________  
 P.O.Box (if available):________________                     e-mail ( if available ):____________________  
 Martial Status:   Single    Married     Divorced      Gender:  male      female         
 Type of Donation:    Volunteer    Autologous     Replacement for patient  Patient file number:_____________       
 First time donation       previous donation     how many times ____ last donation date:____________  
 Donation Type:  regular                       apheresis     
 To Protect your health & the patient receiving blood, please read these questions carefully and answer them accurately:  
 No Question Put √ on the appropriate answer Yes No  
 1 Are you feeling well and healthy today?      
 2 Would you be willing to be a regular donor and accepting blood bank calls whenever there is a need?      
 3 Have you ever rejected as a blood donor before?      
 4 Have you had yellow jaundice, liver disease, hepatitis since age of 11 year old or found to be positive for hepatitis?         
 5 Do you have an infection now or are you taking antibiotics now?      
 6 Have you suffered from a blood disease or had a tendency to bleed?      
 7 Have you had any unexplained fever, swollen glands or weight loss?      
 8 Have you ever suffered from convulsions, seizures or fainting spells?      
 9 Have you or any one of your relatives ever had a disease called CREUTZFELDT-JAKOB DISEASE?(CJD)       
 10 Have you ever taken any growth hormone injection?      
 11 Have you ever had Brain surgery or brain converting graft?      
 12 
From 1980 through 1996, did you spend time more than3 months in UK or have you got any blood transfusion there?  received blood 
products  from the  same country during the same date?      
 13 Have you been under a Doctor's care or taking any medication now?      
 14 Are you a citizen from or have visited a country with endemic of malaria?      
 15 Have you ever had malaria in the past?      
 16 Are you a blood relative of the intended recipient?      
 17 Have you been injected with Bovine (beef) insulin since1980?      
 IN THE LAST YEAR  
 18 Have you traveled abroad?      
 19 Have you ever had any surgery in the past? Or Have you received any blood or blood products?      
 20 Have you had a tattoo or an accidental needle prick?      
 21 Have you come in contact with any one with Hepatitis or HIV?      
 22 Have you had any vaccination recently?      
 23 Have you had any disease or taking any medication now?      
 24 Have you imprisoned or incarceration in a correctional institution for more than 72 consecutive hours?      
 FOR LADIES  
 25 Are you pregnant or have been pregnant in the past 6 weeks?      
 FOR ALL DONORS: you should never give blood if  
 • You are a carrier of Hepatitis "B" or " C" Virus or AIDS  
 • You have ever had sex with another man/woman even safe sex  
 • You have ever had sex with anyone with Hepatitis or HIV even once  
 • You are taking any Narcotic Drugs  
 After reading the above information, do you still feel that Your blood is suitable for blood transfusion? Yes       No   
 Donor acknowledgment       I (name)  _____________________      acknowledge that       • All educational materials was given to me and it has been read and understood,  
 • I was given all opportunity to ask all concerned questions   
 • I have provided accurate information to the best of my knowledge and ability.  
 
• I accepted that blood transfusion services has the full authority to use my blood in helping patient's ,research purpose or in any other purpose that they found it 
useful  
 • I acknowledge that I have no rights to ask for the blood that I donated later.     
 •I am authorizing blood transfusion services staff to collect 450 ml of blood from me.   
 • I accepted that my blood will be tested for the following ( hepatitis B HBsAg, Hepatitis C HCV, AIDS HIV1.2,syphilis and HTLV1.2 ) and HIV1 RNA HCV RNA  
 •I have been informed that there are circumstances in which infectious diseases are not performed  
 • I have been informed that I may be called blood bank within 24 hours time if I feel that my blood should not be used for transfusion.  
 
• If any of these tests or the information recorded on this form indicate that I should no longer donate blood or blood components because of a risk of transmitting 
AIDS or other diseases, my blood will not be used. I will be notified, and my name will be entered on a list of deferred donors. (confidentially )  
       Signature:______________ Date :___________________    
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Standared curve for the ELISA. 
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